Cxcr4 antagonist and use thereof

ABSTRACT

The present invention provides preventive and/or therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its amide, its ester and its salt.

TECHNICAL FIELD

The present invention relates to compounds having CXCR4 antagonisticaction, and to preventive and/or therapeutic medicines containing suchcompounds for cancers and chronic rheumatoid arthritis.

BACKGROUND ART

Many hormones and neurotransmitters regulate vital functions throughspecific receptors existing in cell membranes.

Many of these receptors conduct intracellular signaling through theactivation of coupled guanine nucleotide-binding protein (as may behereafter abbreviated to “G-protein”). Also, these receptors arecollectively called G-protein-coupled receptors (GPCR) or 7trans-membrane receptors (7TMR), as they have common structures havingseven trans-cytomembrane domains.

As one of such G-protein-coupled receptors, a human receptor proteincoded by CXCR4 gene is known [Journal of biological chemistry, Vol. 273,4754 (1998)].

Also, CXCL12/SDF-1α, which is a physiologically active peptidefunctioning as a ligand of the above-mentioned CXCR4, is known [Science,Vol. 261, 600-603 (1993)].

Certain peptidic compounds having antagonistic action against CXCR4 aredisclosed and their anti-HIV activity is described in Fujii,International Publication WO02/20561 Mar. 14, 2003.

Cancer metastasis is one of the critical factors affecting the lifeexpectancy of patients. It is reported that the expression of CXCR4 isenhanced in breast cancer cells, etc., and that the expression ofCXCL12/SDF-1α which is a ligand of CXCR4 is enhanced incancer-metastasized organs (lymph nodes, lungs, livers and bones)[Nature, Vol. 410, 50-56 (2001)]. Also, in chronic rheumatoid arthritis,the infiltration of CD4 positive mermory T-cells into articular cavityfluids affects the progression of the conditions. It is reported that inCD4 positive T-cells in articular cavity fluids of patients sufferingfrom chronic rheumatoid arthritis, the expression of CXCR4 genes isenhanced, and that the expression of CXCL12/SDF-1α genes is enhanced inarticular synovial membrane tissues [Journal of Immunology, Vol. 165,6590-98 (2000)].

The present invention aims at providing novel means using CXCR4antagonistic compounds for the prevention and/or therapy of cancers andchronic rheumatoid arthritis. Also, the present invention provides novelcompounds, in particular, various oligopeptides with common structures,which have preventive and/or therapeutic activity for cancers andchronic rheumatoid arthritis.

DISCLOSURE OF THE INVENTION

The inventors of the present invention were dedicated to studyingpossibilities of solving the above-mentioned problem, and as a result,have discovered that CXCR4 antagonistic compounds previously consideredeffective as chemotherapeutics for AIDS are effective for the preventionand/or therapy of cancers, including metastatic cancers, and chronicrheumatoid arthritis, and have completed the present invention throughfurther research efforts.

That is, the present invention relates to the followings:

(1) Preventive and/or therapeutic medicines for cancers and chronicrheumatoid arthritis, containing a peptide indicated by the followingformula (Ia) or a salt thereof:

In this formula:

A1 is an arginine, lysine, ornithine, citrulline, alanine or glutamicacid residue which may be derivatized at N-terminal, or A1 is deleted;

A2 represents an arginine or glutamic acid residue if A1 is an arginine,lysine, ornithine, citrulline, alanine or glutamic acid residue whichmay be derivatized at N-terminal, or

A2 represents an arginine or glutamic acid residue which may bederivatized at N-terminal if A1 is deleted;

A3 represents an aromatic amino acid residue;

A4, A5 and A9 each independently represents an arginine, lysine,ornithine, citrulline, alanine or glutamic acid residue;

A6 represents a proline, glycine, ornithine, lysine, alanine,citrulline, arginine or glutamic acid residue;

A7 represents a proline, glycine, ornithine, lysine, alanine, citrullineor arginine residue;

A8 represents a tyrosine, phenylalanine, alanine, naphthylalanine,citrulline or glutamic acid residue;

A10 represents a citrulline, glutamic acid, arginine or lysine residue;

A11 represents an arginine, glutamic acid, lysine or citrulline residuewhich may be derivatized at C-terminal;

In the above formula, Cys represents a cysteine residue, Tyr representsa tyrosine residue, the cysteine residue of the 4-position or the13-position can be the combination by disulfide bond, and the amino acidcan be either L or D form.

(2) Preventive and/or therapeutic medicines stated in (1).

In the above formula (Ia):

A1 is an arginine, citrulline, alanine or glutamic acid residue whichmay be derivatized at N-terminal, or A1 is deleted;

A2 represents an arginine or glutamic acid residue if A1 is an arginine,citrulline, alanine or glutamic acid residue which may be derivatized atN-terminal, or A2 represents an arginine or glutamic acid residue whichmay be derivatized at N-terminal if A1 is deleted;

A4 represents an arginine, citrulline, alanine or glutamic acid residue;

A5 represents an arginine, citrulline, alanine, lysine or glutamic acidresidue;

A6 represents a lysine, alanine, citrulline or glutamic acid residue;

A7 represents a proline or alanine residue;

A8 represents a tyrosine, alanine or glutamic acid residue;

A9 represents an arginine, citrulline or glutamic acid residue;

A10 represents a citrulline or glutamic acid residue;

A11 represents an arginine or glutamic acid residue which may bederivatized at C-terminal.

(3) Peptide represented by the following formula (Ib) or a salt thereof:

In this formula:

B1 is a glutamic acid residue which may be derivatized at N-terminal, orB1 is deleted;

B2 represents an arginine or glutamic acid residue if B1 is a glutamicacid residue which may be derivatized at N-terminal, or B2 represents anarginine or glutamic acid residue which may be derivatized at N-terminalif B1 is deleted;

B3 represents an aromatic amino acid residue;

B4, B5 and B9 each independently represents an arginine, lysine,ornithine, citrulline, alanine or glutamic acid residue;

B6 represents a proline, glycine, ornithine, lysine, alanine,citrulline, arginine or glutamic acid residue;

B7 represents a proline, glycine, ornithine, lysine, alanine, citrullineor arginine residue;

B8 represents a tyrosine, phenylalanine, alanine, naphthylalanine,citrulline or glutamic acid residue;

B10 represents a citrulline, glutamic acid, arginine or lysine residue;

B11 represents an arginine, glutamic acid, lysine or citrulline residuewhich may be derivatized at C-terminal;

In the above formula, Cys represents a cysteine residue, Tyr representsa tyrosine residue, the cysteine residue of the 4-position or the13-position can be the combination by disulfide bond, and the amino acidcan be either L or D form.

(4) Peptide or its salt stated in (3).

B1 is a glutamic acid residue which may be derivatized at N-terminal.

(5) Peptide indicated by the following formula (Ic) or a salt thereof:

In this formula:

C1 is an ariginine, lysine, ornithin, citrulline, alanine or glutamicacid residue which may be derivatized at N-terminal, or C1 is deleted;

C2 represents a glutamic acid residue if C1 is an ariginine, lysine,ornithine, citrulline, alanine or glutamic acid residue which may bederivatized at N-terminal, or C2 represents a glutamic acid residuewhich may be derivatized at N-terminal if C1 is deleted;

C3 represents an aromatic amino acid residue;

C4, C5 and C9 each independently represents an arginine, lysine,ornithine, citrulline, alanine or glutamic acid residue;

C6 represents a proline, glycine, ornithine, lysine, alanine,citrulline, arginine or glutamic acid residue;

C7 represents a proline, glycine, ornithine, lysine, alanine, citrullineor arginine residue;

C8 represents a tyrosine, phenylalanine, alanine, naphthylalanine,citrulline or glutamic acid residue;

C10 represents a citrulline, glutamic acid, arginine or lysine residue;

C11 represents an arginine, glutamic acid, lysine or citrulline residuewhich may be derivatized at C-terminal;

In the above formula, Cys represents a cysteine residue, Tyr representsa tyrosine residue, the cysteine residue of the 4-position or the13-position can be the combination by disulfide bond, and the amino acidcan be either L or D form.

(6) Peptide represented by the following formula (Id) or a salt thereof:

In this formula:

D1 is an arginine, lysine, ornithine, citrulline, alanine or glutamicacid residue which may be derivatized at N-terminal, or D1 is deleted;

D2 represents an arginine or glutamic acid residue if D1 is an arginine,lysine, ornithine, citrulline, alanine or glutamic acid residue whichmay be derivatized at N-terminal, or D2 represents an arginine orglutamic acid residue which may be derivatized at N-terminal if D1 isdeleted;

D3 represents an aromatic amino acid residue;

D4 represents a glutamic acid residue;

D5 and D9 each independently represents an arginine, lysine, ornithine,citrulline, alanine or glutamic acid residue;

D6 represents a proline, glycine, ornithine, lysine, alanine,citrulline, arginine or glutamic acid residue;

D7 represents a proline, glycine, ornithine, lysine, alanine, citrullineor arginine residue;

D8 represents a tyrosine, phenylalanine, alanine, naphthylalanine,citrulline or glutamic acid residue;

D10 represents a citrulline, glutamic acid, arginine or lysine residue;

D11 represents an arginine, glutamic acid, lysine or citrulline residuewhich may be derivatized at C-terminal;

In the above formula, Cys represents a cysteine residue, Tyr representsa tyrosine residue, the cysteine residue of the 4-position or the13-position can be the combination by disulfide bond, and the amino acidcan be either L or D form.

(7) Peptide indicated by the following formula (Ie) or a salt thereof:

In this formula:

E1 is an arginine, lysine, ornithine, citrulline, alanine or glutamicacid residue which may be derivatized at N-terminal, or E1 is deleted;

E2 represents an arginine or glutamic acid residue if E1 is an arginine,lysine, ornithine, citrulline, alanine or glutamic acid residue whichmay be derivatized at N-terminal, or E2 represents an arginine orglutamic acid residue which may be derivatized at N-terminal if E1 isdeleted;

E3 represents an aromatic amino acid residue;

E4 and E9 each independently represents an arginine, lysine, ornithine,citrulline, alanine or glutamic acid residue;

E5 represents an arginine or glutamic acid residue;

E6 represents a proline, glycine, ornithine, lysine, alanine,citrulline, arginine or glutamic acid residue;

E7 represents a proline, glycine, ornithine, lysine, alanine, citrullineor arginine residue;

E8 represents a tyrosine, phenylalanine, alanine, naphthylalanine,citrulline or glutamic acid residue;

E10 represents a citrulline, glutamic acid, arginine or lysine residue;

E11 represents an arginine, glutamic acid, lysine or citrulline residuewhich may be derivatized at C-terminal;

In the above formula, Cys represents a cysteine residue, Tyr representsa tyrosine residue, the cysteine residue of the 4-position or the13-position can be the combination by disulfide bond, and the amino acidcan be either L or D form.

(8) Peptide or its salt stated in (7).

E5 represents a glutamic acid residue.

(9) Peptide represented by the following formula (If) or a salt thereof:

In this formula:

F1 is an arginine, lysine, ornithine, citrulline, alanine or glutamicacid residue which may be derivatized at N-terminal, or F1 is deleted;

F2 represents an arginine or glutamic acid residue if F1 is an arginine,lysine, ornithine, citrulline, alanine or glutamic acid residue whichmay be derivatized at N-terminal, or F2 represents an arginine orglutamic acid residue which may be derivatized at N-terminal if F1 isdeleted;

F3 represents an aromatic amino acid residue;

F4, F5 and F9 each independently represents an arginine, lysine,ornithine, citrulline, alanine or glutamic acid residue;

F6 represents a glutamic acid residue;

F7 represents a proline, glycine, ornithine, lysine, alanine, citrullineor arginine residue;

F8 represents a tyrosine, phenylalanine, alanine, naphthylalanine,citrulline or glutamic acid residue;

F10 represents a citrulline, glutamic acid, arginine or lysine residue;

F11 represents an arginine, glutamic acid, lysine or citrulline residuewhich may be derivatized at C-terminal;

In the above formula, Cys represents a cysteine residue, Tyr representsa tyrosine residue, the cysteine residue of the 4-position or the13-position can be the combination by disulfide bond, and the amino acidcan be either L or D form.

(10) Peptide represented by the following formula (Ig) or a saltthereof:

In this formula:

G1 is an arginine, lysine, ornithine, citrulline, alanine or glutamicacid residue which may be derivatized at N-terminal, or G1 is deleted;

G2 represents an arginine or glutamic acid residue if G1 is an arginine,lysine, ornithine, citrulline, alanine or glutamic acid residue whichmay be derivatized at N-terminal, or G2 represents an arginine orglutamic acid residue which may be derivatized at N-terminal if G1 isdeleted;

G3 represents an aromatic amino acid residue;

G4, G5 and G9 each independently represents an arginine, lysine,ornithine, citrulline, alanine or glutamic acid residue;

G6 represents a proline, glycine, ornithine, lysine, alanine,citrulline, arginine or glutamic acid residue;

G7 represents a proline, glycine, ornithine, lysine, alanine, citrullineor arginine residue;

G8 represents a glutamic acid residue;

G10 represents a citrulline, glutamic acid, arginine or lysine residue;

G11 represents an arginine, glutamic acid, lysine or citrulline residuewhich may be derivatized at C-terminal;

In the above formula, Cys represents a cysteine residue, Tyr representsa tyrosine residue, the cysteine residue of the 4-position or the13-position can be the combination by disulfide bond, and the amino acidcan be either L or D form.

(11) Peptide represented by the following formula (Ih) or a saltthereof:

In this formula:

H1 is an arginine, lysine, ornithine, citrulline, alanine or glutamicacid residue which may be derivatized at N-terminal, or H1 is deleted;

H2 represents an arginine or glutamic acid residue if H1 is an arginine,lysine, ornithine, citrulline, alanine or glutamic acid residue whichmay be derivatized at N-terminal, or H2 represents an arginine orglutamic acid residue which may be derivatized at N-terminal if H1 isdeleted;

H3 represents an aromatic amino acid residue;

H4 and H5 each independently represents an arginine, lysine, ornithine,citrulline, alanine or glutamic acid residue;

H6 represents a proline, glycine, ornithine, lysine, alanine,citrulline, arginine or glutamic acid residue;

H7 represents a proline, glycine, ornithine, lysine, alanine, citrullineor arginine residue;

H8 represents a tyrosine, phenylalanine, alanine, naphthylalanine,citrulline or glutamic acid residue;

H9 represents a glutamic acid residue;

H10 represents a citrulline, glutamic acid, arginine or lysine residue;

H11 represents an arginine, glutamic acid, lysine or citrulline residuewhich may be derivatized at C-terminal;

In the above formula, Cys represents a cysteine residue, Tyr representsa tyrosine residue, the cysteine residue of the 4-position or the13-position can be the combination by disulfide bond, and the amino acidcan be either L or D form.

(12) Peptide represented by the following formula (Ii) or a saltthereof:

In this formula:

I1 is an arginine, lysine, ornithine, citrulline, alanine or glutamicacid residue which may be derivatized at N-terminal, or I1 is deleted;

I2 represents an arginine or glutamic acid residue if I1 is an arginine,lysine, ornithine, citrulline, alanine or glutamic acid residue whichmay be derivatized at N-terminal, or I2 represents an arginine orglutamic acid residue which may be derivatized at N-terminal if I1 isdeleted;

I3 represents an aromatic amino acid residue;

I4, I5 and I9 each independently represents an arginine, lysine,ornithine, citrulline, alanine or glutamic acid residue;

I6 represents a proline, glycine, ornithine, lysine, alanine,citrulline, arginine or glutamic acid residue;

I7 represents a proline, glycine, ornithine, lysine, alanine, citrullineor arginine residue;

I8 represents a tyrosine, phenylalanine, alanine, naphthylalanine,citrulline or glutamic acid residue;

I10 represents a glutamic acid, arginine or lysine residue;

I11 represents an arginine, glutamic acid, lysine or citrulline residuewhich may be derivatized at C-terminal;

In the above formula, Cys represents a cysteine residue, Tyr representsa tyrosine residue, the cysteine residue of the 4-position or the13-position can be the combination by disulfide bond, and the amino acidcan be either L or D form.

(13) Peptide represented by the following formula (Ij) or a saltthereof:

In this formula:

J1 is an arginine, lysine, ornithine, citrulline, alanine or glutamicacid residue which may be derivatized at N-terminal, or J1 is deleted;

J2 represents an arginine or glutamic acid residue if J1 is an arginine,lysine, ornithine, citrulline, alanine or glutamic acid residue whichmay be derivatized at N-terminal, or

J2 represents an arginine or glutamic acid residue which may bederivatized at N-terminal if J1 is deleted;

J3 represents an aromatic amino acid residue;

J4, J5 and J9 each independently represents an arginine, lysine,ornithine, citrulline, alanine or glutamic acid residue;

J6 represents a proline, glycine, ornithine, lysine, alanine,citrulline, arginine or glutamic acid residue;

J7 represents a proline, glycine, ornithine, lysine, alanine, citrullineor arginine residue;

J8 represents a tyrosine, phenylalanine, alanine, naphthylalanine,citrulline or glutamic acid residue;

J10 represents a citrulline, glutamic acid, arginine or lysine residue;

J11 represents a glutamic acid, lysine or citrulline residue which maybe derivatized at C-terminal;

In the above formula, Cys represents a cysteine residue, Tyr representsa tyrosine residue, the cysteine residue of the 4-position or the13-position can be the combination by disulfide bond, and the amino acidcan be either L or D form.

(14) Peptide indicated in any of the following items (1)-(58) or a saltthereof:

(1) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH;

(2) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH;

(3) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH;

(4) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-OH;

(5) Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH;

(6) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH;

(7) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-OH;

(8) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-OH;

(9) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(10) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂;

(11) Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(12) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(13) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂;

(14) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂;

(15) H-DGlu-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH;

(16) H-Arg-Glu-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH;

(17) H-Arg-Arg-Nal-Cys-Tyr-Glu-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH;

(18) H-Arg-Arg-Nal-Cys-Tyr-Arg-Glu-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH;

(19) H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-OH;

(20) H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Glu-Cit-Cys-Arg-OH;

(21) H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Glu-OH;

(22) H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(23) H-Arg-Arg-Nal-Cys-Tyr-DGlu-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(24) H-Arg-Arg-Nal-Cys-Tyr-DGlu-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(25) H-DGlu-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(26) H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-DGlu-Arg-Cit-Cys-Arg-NH₂;

(27) H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-DGlu-Cys-Arg-NH₂;

(28) Ac-DGlu-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(29) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-DGlu-Arg-Cit-Cys-Arg-NH₂;

(30) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-DGlu-Cys-Arg-NH₂;

(31) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(32)guanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(33)TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(34) TMguanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(35)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(36)2F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(37) APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(38)desamino-R-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(39) guanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(40) succinyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(41) glutaryl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(42)deaminoTMG-APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(43)nelfinaviryl-succinyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(44)AZT-glutaryl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(45) R—CH2-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(46) H-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(47)TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(48) ACA-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(49) ACA-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH;

(50) H-Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(51) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(52) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(53) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂;

(54)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂

(55)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHMe

(56)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHEt

(57)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHiPr

(58)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-tyramine

In each sequence, the symbol put in the left part of N-terminal aminoacid shows derivatization or non-derivatization of amino group; H showsnon-derivatization, Ac shows acetyl group, guanyl shows guanyl group,succinyl shows succinyl group, glutaryl shows glutaryl group, TMguanylshows tetra-methyl guanyl group, 2F-beozoyl shows 2-fluorobenzoyl group,4F-benzoyl shows 4-fluorobenzoly group, APA shows 5-amino-pentanoylgroup, ACA shows 6-amino-hexanoyl group, desamino-R shows2-desamino-arginyl group, deaminoTMG-APA shows the following formula(II),

nelfinaviryl-succinyl shows the following formula (III)

AZT-glutaryl shows the following formula (IV)

R—CH2 shows the following formula (V)

Arg shows L-arginine residue, Nal show L-3-2(2-naphtyl)alanine residue,Cys shows L-cysteine residue, Tyr shows L-tyrosine residue, Cit showsL-citrulline residue, Lys shows L-lysine residue, DLys shows D-lysineresidue, Pro shows L-proline residue, DCit shows D-citrulline residue,DGlu shows D-glutamic acid residue, Glu shows L-glutamic acid residue, 2cysteine residues are combined by intramolecular disulfide bond, thesymbol attached to the right part of C-terminal amino acid showsderivatization or non-derivatization of carboxyl group, OH showsnon-derivatization, NH₂ shows amidation by amino group, NHMe showsamidation by methyamino group, NHEt shows amidation by ethylamino group,NHiPr shows amidation by isopropylamino group, tyramine shows amidationby p-hydroxy phenyl ethylamino group.

(15) Pharmaceutical products containing any of the peptides stated inany of (3) to (14) or any salt of the peptide.

(16) CXCR4 antagonists belonging to the pharmaceutical products statedin (15).

(17) Preventive and/or therapeutic medicines for cancers or chronicrheumatoid arthritis belonging to the pharmaceutical products stated in(15).

(18) Medicines stated in (17) usable for breast cancer or pancreascancer.

(19) Preventive and/or therapeutic methods for cancers or chronicrheumatoid arthritis by administration to mammalians of effective dosesof a peptide stated in any of (3) to (14) or a salt thereof.

(20) Use of a peptide stated in any of (3) to (14) or a salt thereof forthe manufacturing of preventive and/or therapeutic medicines for cancersor chronic rheumatoid arthritis.

(21) Preventive and/or therapeutic methods for cancers or chronicrheumatoid arthritis by administration to mammalians of effective dosesof a peptide represented by the following formula (Ia) or a saltthereof:

In this formula:

A1 is an arginine, lysine, ornithine, citrulline, alanine or glutamicacid residue which may be derivatized at N-terminal, or A1 is deleted;

A2 represents an arginine or glutamic acid residue if A1 are anarginine, lysine, ornithine, citrulline, alanine or glutamic acidresidue which may be derivatized at N-terminal, or A2 represents anarginine or glutamic acid residue which may be derivatized at N-terminalif A1 is deleted;

A3 represents an aromatic amino acid residue;

A4, A5 and A9 each independently represents an arginine, lysine,ornithine, citrulline, alanine or glutamic acid residue;

A6 represents a proline, glycine, ornithine, lysine, alanine,citrulline, arginine or glutamic acid residue;

A7 represents a proline, glycine, ornithine, lysine, alanine, citrullineor arginine residue;

A8 represents a tyrosine, phenylalanine, alanine, naphthylalanine,citrulline or glutamic acid residue;

A10 represents a citrulline, glutamic acid, arginine or lysine residue;

A11 represents an arginine, glutamic acid, lysine or citrulline residuewhich may be derivatized at C-terminal;

In the above formula, Cys represents a cysteine residue, Tyr representsa tyrosine residue, the cysteine residue of the 4-position or the13-position can be the combination by disulfide bond, and the amino acidcan be either L or D form.

(22) Use of a peptide represented by the following formula (Ia) or asalt thereof for the manufacturing of preventive and/or therapeuticmedicines for cancers or chronic rheumatoid arthritis:

In this formula:

A1 is an arginine, lysine, ornithine, citrulline, alanine or glutamicacid residue which may be derivatized at N-terminal, or A1 is deleted;

A2 represents an arginine or glutamic acid residue if A1 is an arginine,lysine, ornithine, citrulline, alanine or glutamic acid residue whichmay be derivatized at N-terminal, or

A2 represents an arginine or glutamic acid residue which may bederivatized at N-terminal if A1 is deleted;

A3 represents an aromatic amino acid residue;

A4, A5 and A9 each independently represents an arginine, lysine,ornithine, citrulline, alanine or glutamic acid residue;

A6 represents a proline, glycine, ornithine, lysine, alanine,citrulline, arginine or glutamic acid residue;

A7 represents a proline, glycine, ornithine, lysine, alanine, citrullineor arginine residue;

A8 represents a tyrosine, phenylalanine, alanine, naphthylalanine,citrulline or glutamic acid residue;

A10 represents a citrulline, glutamic acid, arginine or lysine residue;

A11 represents an arginine, glutamic acid, lysine or citrulline residuewhich may be derivatized at C-terminal;

In the above formula, Cys represents a cysteine residue, Tyr representsa tyrosine residue, the cysteine residue of the 4-position or the13-position can be the combination by disulfide bond, and the amino acidcan be either L or D form.

The peptidic compounds of the present invention have potent CXCR4antagonistic activity, and show therapeutic effects for cancers andchronic rheumatoid arthritis by inhibiting the interaction of CXCR4 andCXCL12/SDF-1.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the inhibitory activity of TE-14005 against the migrationof breast cancer cells induced by CXCL12. The vertical axis shows themigration of cells (absorption of light: OD550 nm). From the left, itshows the result (mean value±standard deviation, n=2) obtainedrespectively when CXCL12 was not added (negative control), when CXCL12was added (positive control), when CXCL12 and TE-14005 10 nM were added,when CXCL12 and TE-14005 100 nM were added, when CXCL12 and TE-14005 1μM were added, and when CXCL12 and TE-14005 10 μM were added. *indicates the significance of each TE-14005 added group compared withthe positive control group (Williams' test, p 0.025).

FIG. 2 shows the inhibitory activity of TC-14012 against the migrationof breast cancer cells induced by CXCL12. The vertical axis shows themigration of cells (absorption of light: OD550 nm). From the left, itshows the result (mean value±standard deviation, n=2) obtainedrespectively when CXCL12 was not added (negative control), when CXCL12was added (positive control), when CXCL12 and TC-14012 1 nM were added,when CXCL12 and TC-14012 10 nM were added, when CXCL12 and TC-14012 100nM were added, and when CXCL12 and TC-14012 1 μM were added. * indicatesthe significance of each TC-14012 added group compared with the positivecontrol group (Williams' test, p 0.025).

FIG. 3 shows the inhibitory activity of 4Fbenzoyl-TN-14003 against themigration of T-cell originating leukemia cells induced by CXCL12. Thevertical axis shows the migration of cells (the number of cells). Fromthe left, it shows the result (mean value±standard deviation, n=2)obtained respectively when CXCL12 was not added (negative control), whenCXCL12 was added (positive control), when CXCL12 and 4Fbenzoyl-TN-140031 nM were added, when CXCL12 and 4Fbenzoyl-TN-14003 10 nM were added,when CXCL12 and 4Fbenzoyl-TN-14003 100 nM were added, and when CXCL12and 4Fbenzoyl-TN-14003 1 μM were added. * indicates the significance ofeach 4Fbenzoyl-TN-14003 added group compared with the positive controlgroup (Williams' test, p 0.025).

FIG. 4 shows the inhibitory activity of 4Fbenzoyl-TN-14003 against themigration of breast cancer cells induced by CXCL12. The vertical axisshows the migration of cells (absorption of light: OD550 nm). From theleft, it shows the result (mean value±standard deviation, n=2) obtainedrespectively when CXCL12 was not added (negative control), when CXCL12was added (positive control), when CXCL12 and 4Fbenzoyl-TN-14003 10 nMwere added, when CXCL12 and 4Fbenzoyl-TN-14003 100 nM were added, whenCXCL12 and 4Fbenzoyl-TN-14003 1 μM were added, and when CXCL12 and4Fbenzoyl-TN-14003 10 μM were added. * indicates the significance ofeach 4Fbenzoyl-TN-14003 added group compared with the positive controlgroup (Williams' test, p 0.025).

FIG. 5 is a chromatic figure of lung tissue displaying the inhibitoryactivity of 4Fbenzoyl-TN-14003 in a mouse transplanted with human breastcancer cells.

FIG. 5A displays the lungs of the control group (saline administrationgroup).

FIG. 5B is the pictures of the lungs of 4Fbenzoyl-TN-14003administration group.

FIG. 6 shows the inhibitory activity of 4Fbenzoyl-TN-14003 againstmigration of Jurkat cells induced by SDF-1α (CXCL12). The vertical axisshows cell migration (the ratio of migrating cells to the input). Fromthe left, it shows the result obtained respectively when SDF-1α was notadded, when SDF-1α was added, when SDF-1α and 4Fbenzoyl-TN-14003 10 pMwere added, when SDF-1α and 4Fbenzoyl-TN-14003 100 pM were added, whenSDF-1α and 4Fbenzoyl-TN-14003 1 nM were added, when SDF-1α and4Fbenzoyl-TN-14003 10 nM were added, and when SDF-1α and4Fbenzoyl-TN-14003 100 nM were added.

FIG. 7 shows the inhibitory activity of 4Fbenzoyl-TN-14003 againstmigration of mouse splenocytes induced by SDF-1α (CXCL12). The verticalaxis shows cell migration (the ratio of migrating cells to the input).From the left, it shows the result obtained respectively when SDF-1α wasnot added, when SDF-1α was added, when SDF-1α and 4Fbenzoyl-TN-14003 10pM were added, when SDF-1α and 4Fbenzoyl-TN-14003 100 pM were added,when SDF-1α and 4Fbenzoyl-TN-14003 1 nM were added, when SDF-1α and4Fbenzoyl-TN-14003 10 nM were added, and when SDF-1α and4Fbenzoyl-TN-14003 100 nM were added.

FIG. 8 shows the inhibitory activity of 4Fbenzoyl-TN-14003 against mouseDTH reaction induced by SRBC. The vertical axis shows the increase offootpad thickness of by swelling (mean value±standard margin of error,n=7). From the left, it shows the result each of PBS administration(control) group, 4Fbenzoyl-TN-14003 48 μg per-day administration group,4Fbenzoyl-TN-14003 24 μg per-day administration group, and4Fbenzoyl-TN-14003 120 μg per-day administration group. * is P 0.025(comparison with PBS administration group; Williams' test).

FIG. 9 shows the effects of known medicines against mouse collagenarthritis.

FIG. 9A shows fluctuations in body weight [vertical axis: body weightgain (g) (mean value±standard margin of error, n=8), horizontal axis:post-booster days];

FIG. 9B shows fluctuations of the incidence of the disease [verticalaxis: incidence (%) (n=8), horizontal axis: post-booster days];

FIG. 9C shows fluctuations of arthritis score [vertical axis: arthritisscore (mean value±standard margin of error, n=8), horizontal axis:post-booster days];

FIG. 9D shows fluctuations of ankle thickness [vertical axis: anklethickness (mm) (mean value±standard margin of error, n=8), horizontalaxis: post-booster days]. : normal mouse group, : drugnon-administration (control) group, Δ: indomethacin administrationgroup, : ethotrexate administration group, : FK506 administration group;

FIG. 9E shows each drug's effect on hindlimb swelling 2 weeks after thebooster [vertical axis: hindlimb weight (mg) (average amount±standardmargin of error, n=8)]; and

FIG. 9F shows each drug's effect on anti-bovine II collagen IgG2aantibody value 2 weeks after the booster [vertical axis: antibody value(A450) (mean value±standard margin of error, n=8)] [from the left, itshows normal mouse group, drug non-administration (control) group,indomethacin (IND) administration group, methotrexate (MTX)administration group, FK506 administration group]. ## is P 0.01(comparison with normal mice group; t-test), * and ** respectively showP 0.05 and P 0.01 (comparison with drug non-administration group;Dunnett's test).

FIG. 10 shows the activity of 4Fbenzoyl-TN-14003 on mousecollagen-induced arthritis.

FIG. 10A shows fluctuations of the body weight [vertical axis: bodyweight (g) (mean value±standard margin of error), horizontal axis:post-booster days],

FIG. 10B shows fluctuations of the disease incidence [vertical axis:incidence (%), horizontal axis: post-booster days],

FIG. 10C shows fluctuations of arthritis score [vertical axis: arthritisscore (mean value±standard margin of error), horizontal axis:post-booster days],

FIG. 10D shows the fluctuations of ankle thickness [vertical axis: anklethickness (mm) (mean value±standard margin of error), horizontal axis:post-booster days]. : normal mice group (n=8), : drug non-administration(control) group (n=12), Δ: 4Fbenzoyl-TN-14003 administration group(n=11),

FIG. 10E shows the effects of 4Fbenzoyl-TN-14003 on hindlimb swelling 2weeks after the booster [vertical axis: hindlimb weight (mg) (meanvalue±standard margin of error)], and

FIG. 10F shows the effects of 4Fbenzoyl-TN-14003 on the anti-bovine IIcollagen IgG2a antibody value 2 weeks after the booster [vertical axis:antibody value (A450) (mean value±standard margin of error)]. From theleft, it shows normal mouse group (n=8), drug non-administration(control) group (n=12), 4Fbenzoyl-TN-14003 administration group (n=11)].## shows P 0.01 (comparison with normal mice group; t-test), and **shows P 0.01 (comparison with drug non-administration group; t-test).

BEST MODE FOR CARRYING OUT THE INVENTION

The peptides described in this specification have N-terminal(amino-terminal) at the left extremity and C-terminal (carboxyl-terminalat the right extremity in accordance with the customary practice ofpeptide notations.

In this specification and drawings, the representations of amino acids,etc. by brevity codes are made by the use of the codes prescribed byIUPAC-IUB Commission on Biochemical Nomenclature or by the codescustomarily used in the relevant art. Examples of such codes are shownas below. If an optical isomer exists with respect to an amino acid, itrepresents L form unless otherwise expressly specified.

-   -   Gly or G: glycine    -   Ala or A: alanine    -   Val or V: valine    -   Leu or L: leucine    -   Ile or I: isoleucine    -   Ser or S: serine    -   Thr or T: threonine    -   Cys or C: cysteine    -   Met or M: methionine    -   Glu or E: glutamic acid    -   Asp or D: aspartic acid    -   Lys or K: lysine    -   Arg or R: arginine    -   His or H: histidine    -   Phe or F: phenylalanine    -   Tyr or Y: tyrosine    -   Trp or W: tryptophan    -   Pro or P: proline    -   Asn or N: asparagine    -   Gln or Q: glutamine    -   pGlu: pyroglutamic acid    -   Nal: 3-(2-naphthyl)alanine    -   Cit: citrulline    -   DLys: D-lysine    -   DCit: D-citrulline    -   DGlu: D-glutamic acid    -   Me: methyl group    -   Et: ethyl group    -   Bu: butyl group    -   Ph: phenyl group

The substituents, protective group and reagents often used in thisspecification are indicated by the following codes.

-   -   BHA: benzhydrylamine    -   pMBHA: p-methylbenzhydrylamine    -   Tos: p-toluenesulphonyl    -   CHO: formyl    -   HONB: N-hydroxy-5-norbornene-2,3-dicarboximide    -   OcHex: cyclohexyl ester    -   Bzl: benzyl    -   Cl2-Bzl: dichloro-benzyl    -   Bom: benzyloxymethyl    -   Z: benzyloxycarbonyl    -   Br-Z: 2-bromobenzyloxycarbonyl    -   Boc: t-butyloxycarbonyl    -   DCM: dichloromethane    -   HOBt: 1-hydroxybenzotriazole    -   DCC: N,N′-dicyclohexylcarbodiimide    -   TFA: trifluoroacetic acid    -   DIEA: diisopropylethylamine    -   Fmoc: N-9-fluorenylmethoxycarbony    -   DNP: dinitrophenyl    -   Bum: tertiarybutoxymethyl    -   Trt: trityl    -   Ac: acetyl    -   Guanyl: guanyl    -   Succinyl: succinyl    -   glutaryl: glutaryl    -   TMguanyl: tetramethylguanyl    -   2F-benzoyl: 2-fluorobenzoyl    -   4F-benzoyl: 4-fluorobenzoyl    -   APA: 5-aminopentanoyl    -   ACA: 6-aminohexanoyl    -   desamino-Arg: 2-desamino-arginyl        deamino TMG-APA: the following formula (II)        nelfinaviryl-succinyl: the following formula (III)        AZT-glutaryl: the following formula (IV)        R—CH: the following formula (V)

In amino acids of N-terminal peptide, [H—] indicates that terminalaminogroup is not derivatized, and in amino acids of C-terminal peptide,[—OH] indicates that terminal carboxyl group is not derivatized.

The present invention provides preventive and/or therapeutic medicinescontaining CXCR4 antagonistic compounds for cancers and chronicrheumatoid arthritis. The “CXCR4 antagonistic compounds” showanti-cancer activity antagonistically inhibiting the interaction ofCXCR4 and its physiological ligand CXCL12/SDF-1α (e.g. migrationinhibitory activity, invasion inhibitory activity, and anti-metastasisactivity, etc.) or anti-chronic rheumatoid arthritis activity (e.g.migration inhibitory activity), and more particularly, they include thepeptide represented by the following formula (Ia), an amide thereof, anester thereof or a salt thereof (hereinafter as may be collectivelyreferred to as “peptide(s) of the present invention”):

In this formula:

A1 is an arginine, lysine, ornithine, citrulline, alanine or glutamicacid residue which may be derivatized at N-terminal, or A1 is deleted;

A2 represents an arginine or glutamic acid residue if A1 is an arginine,lysine, ornithine, citrulline, alanine or glutamic acid residue whichmay be derivatized at N-terminal, or A2 represents an arginine orglutamic acid residue which may be derivatized at N-terminal if A1 isdeleted;

A3 represents an aromatic amino acid residue;

A4, A5 and A9 each independently represents an arginine, lysine,ornithine, citrulline, alanine or glutamic acid residue;

A6 represents a proline, glycine, ornithine, lysine, alanine,citrulline, arginine or glutamic acid residue;

A7 represents a proline, glycine, ornithine, lysine, alanine, citrullineor arginine residue;

A8 represents a tyrosine, phenylalanine, alanine, naphthylalanine,citrulline or glutamic acid residue;

A10 represents a citrulline, glutamic acid, arginine or lysine residue;

A11 represents an arginine, glutamic acid, lysine or citrulline residuewhich may be derivatized at C-terminal;

In the above formula, Cys represents a cysteine residue, Tyr representsa tyrosine residue, the cysteine residue of the 4-position or the13-position can be the combination by disulfide bond, and the amino acidcan be either L or D form.

A1 in the above-mentioned formula (Ia) represents an arginine, lysine,ornithine, citrulline, alanine or glutamic acid residue (either L or Dform) which may be derivatized at N-terminal, or A1 is deleted, or it ispreferable that A1 is an arginine, citrulline, alanine or D-glutamicacid residue, or A1 is deleted.

Examples of “peptides derivatized at N-terminal” include, but are notlimited to, those protected by formyl group; acyl group, e.g., acetylgroup, propionyl group, butyryl group, pentanoyl group, C2-6alkanoylgroup such as hexanoyl group, benzoyl group, arylcarbonyl group such assubstituted benzoyl group (e.g.: 2-fluorobenzoyl, 3-fluorobenzoyl group,4-fluorobenzoyl group, 2-bromobenzoyl group, 3-bromobenzoyl group,4-bromobenzoyl group, 2-nitrobenzoyl group, 3-nitrobezoyl group,4-nirtobenzoyl group), succinyl group, glutaryl group; nicotinyl group;isonicotinyl group; alkylsulfonyl group (e.g.: methanesulfonyl group,ethanesulfonyl group, propanesulfonyl group, camphorsulfonyl group);arylsulfonyl group (e.g.: p-toluenesulfonyl group,4-fluorobenzenesufonyl group, mesitylenesulfonyl group,4-aminobenzenesulfonyl group, dansyl group, 4-bromobenzenesulfonylgroup) etc. Or, the amino acid group of N-terminal may be deleted.

A2 in the above-mentioned formula (Ia) represents an arginine orglutamic acid residue (either L or D form) if A1 is an arginine, lysine,ornithine, citrulline, alanine or glutamic acid residue (either L or Dform) which may be derivatized at N-terminal, or A2 represents anarginine or glutamic acid residue (either L or D form) which may bederivatized at N-terminal if A1 is deleted, or it is preferable that A2is an arginine or glutamic acid residue if A1 is an arginine,citrulline, alanine or glutamic acid residue which may be derivatized atN-terminal, or A2 is an arginine or glutamic acid residue which may bederivatized at N-terminal if A1 is deleted.

Examples of “peptides derivatized at N-terminal” include, but are notlimited to, the same ones as those mentioned in A1.

A3 in the above-mentioned formula (Ia) represents an aromatic amino acidresidue (e.g., phenylalanine, tryptophan, 3-(2-naphthyl)alanine,tyrosine, 4-fluorophenylalanine, 3-(1-naphthyl)alanine (either L or Dform), or preferably, A3 represents phenylalanine, tryptophan or3-(2-naphthyl)alanine.

A4 in the above-mentioned formula (Ia) represents an arginine, lysine,ornithine, citrulline, alanine or glutamic acid residue (either L or Dform), or it is preferable that A4 is an arginine, citrulline, alanineor L- or D-glutamic acid residue.

A5 in the above-mentioned formula (Ia) represents an arginine, lysine,ornithine, citrulline, alanine or glutamic acid residue, or it ispreferable that A5 is an arginine, citrulline, alanine, lysine orglutamic acid residue.

A6 in the above-mentioned formula (Ia) represents a proline, glycine,ornithine, lysine, alanine, citrulline, arginine or glutamic acidresidue (either L or D form), or it is preferable that A6 is a D-lysine,D-alanine, D-citrulline or D-glutamic acid residue.

A7 in the above-mentioned formula (Ia) represents a proline, glycine,ornithine, lysine, alanine, citrulline or arginine residue (either L orD form), or it is preferable that A7 is a proline or alanine residue.

A8 in the above-mentioned formula (Ia) represents a tyrosine,phenylalanine, alanine, naphthylalanine, citrulline or glutamic acidresidue (either L or D form), or it is preferable that A8 is a tyrosine,alanine or D-glutamic acid residue.

A9 in the above-mentioned formula (Ia) represents an arginine, lysine,ornithine, citrulline, alanine or glutamic acid residue (either L or Dform), or it is preferable that A9 is an arginine, citrulline orglutamic acid residue.

A10 in the above-mentioned formula (Ia) represents a citrulline,glutamic acid, arginine or lysine residue (either L or D form), or it ispreferable that A10 is a citrulline or D-glutamic acid residue.

A11 in the above-mentioned formula (Ia) represents an arginine, glutamicacid, lysine or citrulline residue (either L or D form) which may bederivatized at C-terminal, or it is preferable that A11 is an arginineor glutamic acid residue which may be derivatized at C-terminal.

“Derivatization at C-terminal” includes, without limitation, amidation(—CONH₂, —CONHR, —CONRR′) and esterification (—COOR). Herein, R and R′in amides and esters include, for example, C1-6 alkyl group such asmethyl, ethyl, n-propyl, isopropyl, or n-butyl, C3-8 cycloalkyl groupsuch as cyclopentyl, cyclohexyl, C6-12 aryl group such as phenyl andα-naphthyl, phenyl-C1-2 alkyl group such as benzyl, phenethyl or C7-14aralkyl group such as C1-2 alkyl group such as α-naphthyl methyl group,and additionally, pivaloyloxymethyl group which is generally used as anoral bioavailable ester.

If a peptide of the present invention has carboxy groups (orcarboxylates) at side-chain terminals other than C-terminal, the peptidehaving amidated or esterificated carboxy groups at side-chain terminalsis included in the peptides of the present invention. As the amides andesters in this case, for example, the amides and esters exemplified inA11 are similarly used. Also, the peptides of the present inventioninclude peptides in which substituents (e.g. —OH, —SH, amino group,imidazole group, indole group, guanidino group, etc.) on theintramolecular amino acid side chains are protected by suitableprotective group (e.g. C1-6 acyl group, C2-6 alkanoyl such as formylgroup, acetyl group, etc.), or complex peptides such as glycopeptidescombined with sugar chain in the above-mentioned peptides.

Salts of the peptides of the present invention include physiologicallyacceptable salts of acids or bases and particularly, physiologicallyacceptable acid addition salts are preferable. Such salts areexemplified by salts of inorganic acids (e.g. hydrochloric acid,phosphoric acid, hydrobromic acid, sulfuric acid), or salts of organicacids (e.g. acetic acid, formic acid, propionic acid, fumaric acid,maleic acid, succinic acid, tartaric acid, citric acid, malic acid,oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid).

A peptide of the present invention is a new peptide if any one of A1 toA11 indicated in the above-mentioned formula (Ia) is the following:

-   -   (i) If A1 is a glutamic acid residue or is deleted (i.e. the        same as the above-mentioned formula (Ib));    -   (ii) If any one of A2, A4, A6, A8 and A9 is a glutamic acid        residue (i.e. the same as any of the above-mentioned formula        (Ic) to (Ig)):    -   (iii) If A5 is an arginine or glutamic acid residue (i.e. the        same as the above-mentioned formula (Ih)):    -   (iv) If A10 is a glutamic acid, arginine or lysine residue (i.e.        the same as the above-mentioned formula (Ii)):    -   (v) If A11 is a glutamic acid, lysine or citrulline residue        (i.e. the same as the above-mentioned formula (Ij)).

The above-mentioned amino acid residues may be either L or D form.

As the peptides of the present invention, preferably the peptides havingthe amino acid sequences of the following (1) to (58) (in each sequence,two cysteine residues are coupled by the disulfide bond) areexemplified.

-   (1) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH    (AcTC14003)-   (2) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH    (AcTC14005)-   (3) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH    (AcTC14011)-   (4) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-OH    (AcTC14013)-   (5) Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH    (AcTC14015)-   (6) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH    (AcTC14017)-   (7) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-OH    (AcTC14019)-   (8) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-OH    (AcTC14021)-   (9) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (AcTC14012)-   (10) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂    (AcTC14014)-   (11) Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (AcTC14016)-   (12) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (AcTC14018)-   (13) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂    (AcTC14020)-   (14) Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂    (AcTC14022)-   (15) H-DGlu-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH    (TE14001)-   (16) H-Arg-Glu-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH    (TE14002)-   (17) H-Arg-Arg-Nal-Cys-Tyr-Glu-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH    (TE14003)-   (18) H-Arg-Arg-Nal-Cys-Tyr-Arg-Glu-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH    (TE14004)-   (19) H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-OH    (TE14005)-   (20) H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Glu-Cit-Cys-Arg-OH    (TE14006)-   (21) H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Glu-OH    (TE14007)-   (22) H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TE14011)-   (23) H-Arg-Arg-Nal-Cys-Tyr-DGlu-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TE14012)-   (24) H-Arg-Arg-Nal-Cys-Tyr-DGlu-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TE14013)-   (25) H-DGlu-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TE14014)-   (26) H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-DGlu-Arg-Cit-Cys-Arg-NH₂    (TE14015)-   (27) H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-DGlu-Cys-Arg-NH₂    (TE14016)-   (28)    Ac-DGlu-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (AcTE14014)-   (29)    Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-DGlu-Arg-Cit-Cys-Arg-NH₂    (AcTE14015)-   (30)    Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-DGlu-Cys-Arg-NH₂    (AcTE14016)-   (31) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TF1: AcTE14011)-   (32)    guanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TF2: guanyl-TE14011)-   (33)    TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TF3: TMguanyl-TE14011)-   (34)    TMguanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TF4: TMguanyl-TE14011 (2-14))-   (35)    4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TF5: 4F-benzoyl-TE14011)-   (36)    2F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TF6: 2F-benzoyl-TE14011)-   (37) APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TF7: APA-TE14011 (2-14))-   (38)    desamino-R-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TF8: desamino-R-TE14011 (2-14))-   (39) guanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TF9: guanyl-TE14011 (2-14))-   (40)    succinyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TF10: succinyl-TE14011 (2-14))-   (41)    glutaryl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TF11: glutaryl-TE14011 (2-14))-   (42)    deaminoTMG-APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TF12: deaminoTMG-APA-TE14011 (2-14))-   (43)    nelfinaviryl-succinyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TF13: nelfinaviryl-succinyl-TE14011 (2-14))-   (44)    AZT-glutaryl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TF14: AZT-glutaryl-TE14011 (2-14))-   (45) R—CH2-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TF15: H-Arg-CH2NH-RTE14011 (2-14))-   (46) H-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TF17: TE14011 (2-14))-   (47)    TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TF18: TMguanyl-TC14012)-   (48)    ACA-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TF19: ACA-TC14012)-   (49) ACA-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH    (TF20: ACA-T140)-   (50) H-Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (TZ14011)-   (51) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (AcTZ14011)-   (52) Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (AcTN14003)-   (53) Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (AcTN14005)-   (54)    4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂    (4F-benzoyl-TN14003)-   (55)₄F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHMe    (4F-benzoyl-TN 14011-Me)-   (56)    4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHEt    (4F-benzoyl-TN 14011-Et)-   (57)₄F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHiPr    (4F-benzoyl-TN 14011-iPr)-   (58)    4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-tyramine    (4F-benzoyl-TN14011-tyramine)

A peptide of the present invention includes a peptide or its amide,ester or salt containing the amino acid sequence which is thesubstantially same amino acid sequence as the sequence of any of theabove-mentioned peptides. Here, “the substantially same amino acidsequence” means the amino acid sequence qualitatively identical in theactivity of the peptide (e.g. the inhibitory activity on the interactionof a ligand and a receptor) or the anti-cancer activity of the peptide(e.g. migration inhibitory activity, invasion inhibitory activity andanti-metastasis activity) or the anti-rheumatoid arthritis activity(e.g. migration inhibitory activity) or the like. Accordingly,quantitative variances are acceptable to some extent (e.g. about 0.01 to100 times, preferably 0.5 to 20 times, or more preferably 0.5 to 2times). Therefore, one or more of the amino acids in the amino acidsequences indicated in any of the above-mentioned formula (Ia) to (Ij)and (1) to (58) can have variances, so far as they have any of theabove-mentioned properties. That is to say, in the present invention,any peptide (variant peptide) resulting from the variance in the aminoacid sequence such as substitution, deletion or insertion (addition)etc. which brings about any serious (significant) change (i.e. aqualitatively different change, or a qualitatively identical butquantitatively significantly different change) in the physiologicalproperty or chemical property of the original (non-variant) peptide isdeemed as substantially same as the original (non-variant) peptidehaving no such variance, and, the amino acid sequence of such variantpeptide is deemed as substantially same as the amino acid sequence ofthe original (non-variant) peptide.

It is a well-known fact that generally, the change such as substitution,deletion or insertion (addition) of an amino acid in a peptide sequenceoften does not make a great (notable) change to physiological propertyor chemical property of such peptide. Such substitution is exemplifiedby the substitution of a certain amino acid by another amino acid ofsimilar nature (property), and generally, it is considered that if thesubstitution is made between amino acids having greater similarity intheir properties, so much smaller the changes caused by suchsubstitution is in the properties of pre-substituted peptides.

Amino acids are classified, using the similarity of their properties asto one of the criteria, into the following classes, for example: (i)nonpolar (hydrophobic) amino acids (examples: alanine, leucine,isoleucine, valine, proline, phenylalanine, tryptophan, methionine,etc.); (ii) polar (neutral) amino acids (examples: glycine, serine,threonine, cysteine, tyrosine, asparagine, glutamine, etc.); (iii)(basic) amino acids carrying positive electric charge (examples:arginine, lysine, histidine, etc.); (iv)) (acidic) amino acids carryingnegative electric charge (examples: asparatic acid, glutamic acid,etc.), and accordingly, amino acid substitution within each class can beconservative with regard to the property of a peptide (namely,substitution generating “substantially same” amino acid sequences).

In other words, “substantially same amino acid sequences” may include:

-   -   (i) amino acid sequences wherein 1 or more, preferably 1 to 10,        more preferably 1 to 5 amino acids were substituted by other        amino acids in the amino acid sequences indicated in the        above-mentioned formula (Ia) to (Ij) and (1) to (58);    -   (ii) amino acid sequences wherein 1 to 7, preferably 1 to 5,        more preferably 1 to 3 amino acids were deleted in the amino        acid sequences indicated in the above-mentioned formula (Ia) to        (Ij) and (1) to (58);    -   (iii) amino acid sequences wherein 1 to 15, preferably 1 to 10,        more preferably 1 to 5 amino acids were added (inserted) in the        amino acid sequences indicated in the above-mentioned formula        (Ia) to (Ij) and (1) to (58); or    -   (iv) peptides including modifications to constitutive amino        acids (particularly, the side chains thereof) among the peptides        having the amino acid sequences indicated in above (i), (ii) or        (iii), or esters thereof or salts thereof.

A peptide of the present invention, if and when the substitution,deletion, insertion (addition), modification, etc. of above (i) to (iv)is intentionally or incidentally provided in the amino acid sequencethereof, can be varied to a stable peptide against heat or protease or ahigh-activity peptide having more enhanced inhibitory activity. Thepeptides of the present invention include also these variant peptides oramides thereof, esters thereof or salts thereof.

Furthermore, among the peptides of the present invention are the peptideconsisting of the amino acid sequence indicated in any of theabove-mentioned formula (Ia to Ij) and (1) to (58), and the peptidecontaining the amino acid sequence sharing the homology of about 50 to99.9% (preferably, 70 to 99.9%, more preferably 90 to 99.9%) with theforegoing amino acid sequence and having the activities of substantiallysame nature as the peptide consisting of the amino acid sequenceindicated in any of the above-mentioned formula (Ia to Ij) and (1) to(58), or amides thereof, esters thereof or salts thereof. Suchactivities include, for example, inhibitory activities of the peptidessuch as an inhibitory activity on the binding of a ligand to itsreceptor, a signaling inhibitory activity. The inhibitory activities of“substantially same nature” mean that the properties such as theinhibitory activity on the ligand binding to the receptor are of thesame nature. Therefore, it is acceptable even if non-significanteffectiveness levels of the inhibitory activity on the ligand binding tothe receptor are found, and it is not matter even if there aredifferences in molecular weights.

The amides, esters or salts of the peptide having the amino acidsequence indicated in any of the above-mentioned formula (1) to (58)include the same ones as are exemplified for the peptide indicated inthe above-mentioned formula (Ia). Preferably, the peptide having theamino acid sequence indicated in any of the above-mentioned formula (1)to (58) is better if the carboxyl group of the C-terminal amino acidresidue is amidated.

The peptides of the present invention including the peptide containingthe amino acid sequence indicated in any of the above-mentioned formula(1) to (58) can be produced by conventionally known methods ofsynthesizing peptides. For the syntheses of peptides, either solid phasepeptide synthesis or liquid phase synthesis may be utilized. Namely, anexpected peptide can be produced by condensing a partial peptide able toconstitute a peptide or an amino acid with remaining portions, and ifthe product has a protecting group, by eliminating the protecting group.As the known condensation methods and elimination of protecting groups,the following examples (1) to (5) are included:

-   (1) M. Bodanszky and M. A. Ondetti, Peptide Synthesis, Interscience    Publishers, New York (1966).-   (2) Schroeder and Luebke, The Peptide, Academic Press, New York    (1965).-   (3) N. Izumiya, et. al., Peptide Synthesis, Basics and Practice,    Maruzen, Tokyo (1975).-   (4) H. Yajima and S. Sakakibara, Seikagaku-Jikken-Koza I, Protein    Chemistry IV, Tokyo Kagakudojin, Tokyo, pp 205 (1977).-   (5) H. Yajima, Zoku-Iyakuhin-no-Kaihatsu, Vol. 14, Peptide    Synthesis, Hirokawa Publishing Co., Tokyo (1991).

As practical methods for syntheses of peptides, the following examplescan be given: Generally, commercially available resins for synthesis ofpolypeptides can be used. Such resins include, for example, chloromethylresin, hydroxymethyl resin, benzhydroxylamine resin, aminomethyl resin,4-hydroxybenzylalcohol resin, 4-methylbenzhydroxylamine resin, PAMresin, 4-hydroxymethylmethylphenylacetoamidomethyl resin, polyacrylamideresin, 4-(2′,4′-dimetoxyphenyl-hydroxymethyl)phenoxy resin,4-2′,4′-dimetoxyphenyl-Fmoc aminoethylphenoxy resin, etc. Using suchresin, an amino acid with suitably protected α-amino group and sidechain functional group is condensed on the resin to the sequence of theexpected polypeptide in accordance with conventionally knowncondensation methods. In the last stage of the reaction, the polypeptideis cleared from the resin and simultaneously various protective groupsare removed, and then, by carrying out intramolecular disulfidebond-forming reaction in highly diluted solution, the expectedpolypeptide or amide thereof is obtained. For the above-mentionedcondensation of the protected amino acid, various activated reagentsusable for the syntheses of polypeptides can be used, but, it isparticularly better to use carboxyimides. Among such carboxyimides areDCC, N,N′-diisopropylcarbodiimide,N-ethyl-N′-(3-dimethylaminopropyl)cabodiimde, etc. For the activation bythese, together with racemization inhibitory additives (for example,HOBt, HOOBt), a protected amino acid is added directly to the resin, orafter activating the protected amino acid as symmetric acid anhydride orHOBt ester or HOOBt ester, it can be added to ester resin.

Solvents used for the activation of protected amino acids and thecondensation with resins can be chosen from among the solvents known tobe usable for polypeptide condensation reactions. For example, acidamides such as N,N-dimethylformamide, N,N-dimethylacetoamide andN-methylpyrrolidone, halogenated hydrocarbons such as methylene chlorideand chloroform, alcohols such as trifluoroethanol, sulfoxides such asmethyl sulfoxide, ethers such as pyridine, dioxane and tetrahydrofuran,nitriles such as acetonitrile and propionitrile, esters such as methylacetate and ethyl acetate, or appropriated mixtures of the foregoingsare used. A solvent used for activation of a protected amino acid or itscondensation with resin can be selected from among the solvents known tobe usable for condensing reactions of polypeptides. The reactiontemperature is appropriately set within the scope known to be applicableto polypeptide bond forming reactions, usually, at −20° C. to 50° C.Activated amino acid derivatives are usually used at 1.5 to 4 timesexcess. According to the result of tests adopting ninhydrin reaction, ifthe condensation is insufficient, the repetition of condensationreactions without eliminating protective groups can lead to sufficientcondensation. If sufficient condensation is attained by the repetitionof reactions, unreacted amino acids can be acetylated by the use ofacetic anhydride or acetylimidazole.

The protective group of the amino group used as ingredients include, forexample, Z, Boc, tertialypentyloxycarbony, isobornyloxycarbonyl,4-methoxybenzyloxycabonyl, Cl-Z, Br-Z, adamantyloxycabonyl,trifluoroacetyl, phtaloyl, formyl, 2-nitrophenylsulphenyl,diphenylphosphinothioyl, Fmoc, etc. Carboxyl group can be protected, forexample, by alkyl esterification (e.g. straight-chain, branching orcircular alkyl esterification of methyl, ethyl, propyl, butyl,tertialbutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,2-adamantyl, etc.), aralkyl esterification (e.g. benzylester,4-nitrobenzylester, 4-methoxybenzylester, 4-chlorbenzylester, benzhydrylesterification), phenacylesterification, benzylcarbonylhydrazidation,tertialybutoxycarbonylhydrazidation, tritylhydrazidation, etc. Thehydroxyl group of serine can be protected, for example, byesterification or etherification. The groups suitable for thiseterification include, for example, groups derivatized from carboxylicacid such as lower alkanoyl group such as acetyl group, aroyl group suchas benzoyl group, benzyloxycarbonyl group, ethoxycarbonyl group. Thegroups suitable for etherification include, for example, benzyl group,tetrahydropiranyl group, tertiarybutyl group, etc. As the protectivegroups of phenolic OH group of tyrosine, for example, Bzl, C12-Bzl,2-nitrobenzyl, Br-Z, tertiarlybutyl, etc. are used. As the protectivegroups of imidazole of histidine, for example, Tos,4-methoxy-2,3,6-trimethylbenzenesulfonyl, DNP, benzyloxymethyl, Bum,Boc, Trt, Fmoc etc. are used.

Ingredients with activated carboxyl groups include, for example,corresponding acid anhydride, azide, active ester [ester of alcohol(e.g. pentachlorophenol, 2,4,5-trichlorophenol, 2,4-dinitrophenol,cyanomethylalcohol, p-nitrophenol, HONB, N-hydroxysuccimide,N-hydroxyphtalimide, HOBt)] are used. Ingredients with activated aminogroup include, for example, corresponding phosphoric amide. As themethods to remove (elimiate) protective groups, for example, catalyticreduction in hydrogen airstream in the presence of a catalyst such asPd-black or Pd-carbon, acid treatment by anhydrous hydrogen fluoride,methanesulfonic acid, trifluoromethanesulfonic acid, trifluoroaceticacid or a mixture thereof, etc, base treatment by diisopropylethylamine,triethylamine, piperidine, piperadine, etc., and reduction by natrium inliquid ammonia are used. Elimination reaction by the above-mentionedacid treatment is done generally at the temperature of about −20° C. to40° C., but in the acid treatment, it is effective to add a cationtrapping agent such as anisole, phenol, thioanisole, m-cresol, p-cresol,dimethylsulfide, 1,4-butanedithiol, 1,2-ethanedithiol. 2,4-dinitrophenylgroup used as the protective group of imidazole of histidine is removedby thiophenol treatment. Formyl group used as the protective group ofindole of tryptophan is removed by elimination of protection by theabove-mentioned acid treatment in the presence of 1,2-ethanedithiol,1,4-butanedithiol, etc. and also is removed by alkaline treatment bydilute sodium hydroxide solution, dilute ammonia, etc.

Protection and protective group of functional groups not to be involvedin the reaction of ingredients, and elimination of such protectivegroup, and activation of functional groups to be involved in thereaction, etc. can be appropriately selected from among conventionallyknown groups or conventionally known measures. As alternative methods toobtain amides of polypeptides, there is, for example, a method tomanufacture, after amidating and protecting α-carboxyl group ofcarboxy-terminal amino acid and then extending the peptide chain to thedesired chain length on the side of amino group, a polypeptideeliminating the protective group of α-amino group of N-terminal of suchpeptide chain and a polypeptide eliminating the protective group ofcarboxyl group of C-terminal, and then these two peptides are condensedin the above-mentioned mixed solvent. The details of the condensationreaction are the same as described above. After purifying the protectedpolypeptide obtained by the condensation, the desired raw polypeptidecan be obtained by eliminating all the protective groups by theabove-mentioned method. Having purified this raw polypeptide usingvarious known purification methods, if the main fraction isfreeze-dried, an amide type of the desired polypeptide can be obtained.To get an ester type of the polypeptide, for example, make an amino acidester by condensing α-carboxyl group of carboxy-terminal amino acid withthe desired alcohols, and then, the ester type of the desiredpolypeptide can be obtained in the same way as the amide type of thepolypeptide.

After the reaction, the peptides of the present invention can bepurified and isolated by combining usual purification methods such assolvent extraction, distillation, column chromatography, liquidchromatography, re-crystallization, etc. If a peptide obtained by theabove-mentioned methods is a salt-free type, it can be converted to asuitable salt by known methods, or if such peptide is a salt, it can beconverted to a salt-free type by known methods.

Preferably, the new peptides of the present invention having the aminoacid sequences indicated in the above-mentioned formula (1) to (58) canbe manufactured by the methods described in the below-mentionedpractical examples or similar methods. Also, the peptides of the presentinvention can be manufactured by the methods described in theInternational Publication No. 02/20561 Pamphlet or similar methods.

In the event that the peptides of the present invention are used ashuman drugs or veterinary drugs, usual usages may be applied. Forexample, according to need, they may be used by the oral route in theforms of sugar-coated tablets, capsules, elixirs, micro-capsulatedformulations, etc. or by the parenteral route in the injectable forms ofsterile solutions made of water or other pharmacologically acceptableliquid, suspensions, etc. For example, the peptides of the presentinvention can be manufactured as drugs by incorporating physiologicallyacceptable carriers, flavoring compound, excipients, vehicles,preservatives, stabilizers, binding agents in the unit dosageformulation forms required for the generally accepted pharmaceuticalmanufacturing. The quantity of any active ingredient in such drugsshould be the optimal amount within the instructed scope.

Additives which can be incorporated into tablets, capsules, etc.include, for example, binding agents such as gelatin, cornstarch,tragacanth gum and gum Arabic, diluting agents such as crystallinecellulose, swelling agents such as cornstarch, gelatin and alginic acid,lubricant agents such as magnesium stearate, sweetening agents such assucrose, lactose or saccharine, and flavoring agents such as peppermint,akamono oil or cherry. If the preparation form is capsules, it cancontain a liquid carrier such as oil in addition to the above-mentionedmaterials. Sterile composition for injection can be formulated inaccordance with usual pharmaceutical manufacturing practices, bydissolving or suspending active ingredients or natural vegetable oilssuch as sesame oil and copra oil in the vehicles such as injectionsolvents.

As watery solutions for injections, for example, isotonic solutionscontaining physiological saline, glucose and other adjunctive agents(e.g., D-sorbitol, D-mannitol, sodium chloride, etc.) can be used, andalso can be used together with a suitable solubilizing agent such asalcohol (e.g., ethanol), polyalcohol (e.g., propylene glycohol,polyethylene glycohol), nonionic surfactant (e.g., Polysorbate 80™,(HCO-50) etc. Oily solutions include sesame oil, soybean oil, etc. andcan be used together with solubilizing agents such as benzyl benzoateand benzylalcohol. They can also be combined with a buffering agent(e.g., phosphate buffer solution, sodium acetate buffer solution), asoothing agent (e.g., benzalkonium chloride, procaine hydrochloride,etc.), a stabilizer (e.g., human serum albumine, polyethylene glycohol,etc.), a preservative (e.g., benzylalcohol, phenol, etc.), anantioxidant, etc. A prepared injection is sterilely filled into anampoule.

The pharmaceutical preparations manufactured as above are safe andlow-toxic, and accordingly, can be administered to, for example, humansand mammals (e.g., mice, rats, guinea pigs, rabbits, sheep, swines,cows, cats, dogs, monkeys, hamadryas, chimpanzees, etc.).

The dose of a peptide of the present invention differs depending on thedisease condition, etc. The dose in oral administration is usually about0.1 to 1000 mg per one time per 60 kg of the body weight, preferablyabout 1.0 to 500 mg, and more preferably about 1.0 to 200 mg. The singledose in parenteral administration per 60 kg of the body weight differsdepending on the administration subject, disease condition,administration method, etc.; for example, in case of injection, usuallyabout 0.01 to 300 mg, preferably about 0.1 to 200 mg, and morepreferably about 0.1 to 100 mg per one time may be administeredintravenously. For other animals, the dose based on 60 kg of the bodyweight can be administered.

The peptides of the present invention have an anti-cancer activity, i.e.an activity for inhibiting movement of cancer cells and a cancermetastasis inhibitory activity. That is to say, the peptides of thepresent invention, as clearly seen in the below-mentioned practicalexamples, can be used as drugs for prevention and therapy of cancers,especially cancer metastasis, since they have a cancer metastasisinhibitory activity. Accordingly, the peptides of the present inventionas anti-cancer drugs are useful for the amelioration, prevention andtherapy of oral cancer, throat cancer, lip cancer, lingual cancer,gingival cancer, nasopharyngeal cancer, esophageal cancer, gastriccancer, small intestinal cancer, large intestinal cancer includingcolorectal cancer, liver cancer, gallbladder cancer, pancreatic cancer,nasal cancer, lung cancer, bone cancer, soft tissue cancer, skin cancer,melanoma, breast cancer, uterine cancer, ovarian cancer, prostatecancer, testicular cancer, penile cancer, bladder cancer, kidney cancer,brain cancer, thyroid cancer, lymphoma, leukemia, etc. Also, thepeptides of the present invention have an anti-chronic rheumatoidarthritis activity, i.e., an inhibitory effect on T-cell movement. Inother words, the peptides of the present invention, as clearly seen inthe below-mentioned practical examples, can be used as drugs for theprevention and therapy of chronic rheumatoid arthritis, since they havean inhibitory action on T-cell movement. Thus, the peptides of thepresent invention are useful as drugs for the amelioration, preventionand therapy of chronic rheumatoid arthritis.

It is well-known that CXCR4 antagonistic compounds have an anti-viralactivity. Accordingly, it would be obvious to the concerned industrythat the peptides of the present invention can be used as preventive andtherapeutic drugs for viral infectious disease (e.g. AIDS, SARS, etc.).

The use of the peptides of the present invention as anti-cancer drugscan be made concomitantly with other anti-cancer drugs (for example,chemotherapeutic drugs, immunotherapeutic drugs, or drugs inhibiting theactivity of cell growth factors and their receptors) etc. (hereafterreferred to as “concomitant drugs”).

A peptide of the present invention exhibits a beneficial anti-canceractivity when used in a single preparation form, but, the activity canbe further enhanced when used together with one or more of theabove-mentioned concomitant drugs (concomitant use of multiple drugs).

As the said “chemotherapeutic drugs”, alkylating drugs, antimetabolites,anticancer antibiotics and plant-derived anti-cancer drugs can beexemplified.

Included in the examples of “alkylating drugs” are nitrogen mustard,nitrogen mustard-N-oxide hydrochloride, chlorambutyl, cyclophosphamide,ifosfamide, thiotepa, carboquone, improsulfan tosylte, busulfan,nimustine hydrochloride, mitobronitol, melphalan, dacarbazine,ranimustine, estramustine sodium phosphate, triethylenmelamine,carmustine, lomustine, streptozocin, pipobroman, etoglucide,altretamine, ambamustin, dibrospidium hydrochloride, fotemustin,prednimustin, pumitepa, ribomustin, temozolomide, treosulphan,trophosphamide, zinostatin stimalamer, carboquone, adzelecin,systemstin, bizelesin, platinum complex (carboplatin, cisplatin,miboplatin, nedaplatin, oxaliplatin, etc.).

“Antimetabolites” include, for example, mercaptopurine, 6-mercaptopurineriboside, thioinosine, methotrexate, enocitabine, cytarabine, cytarabineocfosfate, ancitabine hydrochloride, 5-FU agents (e.g. fluorouracil,tegafur, UFT, doxifluridine, carmofur, galocitabine, emitefur, etc.),aminopterin, calcium leucovorin, tabloid, butocin, calcium folinate,calcium levofolinate, cladribine, emitefur, fludarabine, gemcitabine,hydroxycarbamide, pentostatin, piritrexim, idoxuridine, mitoguzaon,thiazofurin, ambamustin and gemicitabine.

“Anticancer antibiotics” include, for example, antracycline anti-canceragents (doxorubicine hydrochloride, daunorubicin hydrochloride,aclarubicin hydrochloride, pirarubicin hydrochloride, epirubicinhydrochloride, etc.), actinomycin D, actinomycin C, mitomycin C,chromomycin A3, bleomycin hydrochloride, bleomycin sulfate, pleomycinsulfate, neocarzinostatin, mithramycin, sarcomycin, carzinophilin,mitotane, zorbicin hydrochloride, mitoxantrone hydrochloride andidarubicin hydrochloride.

“Plant-derived anti-cancer agents” include, for example, vinca alkaloidanti-cancer agents (vinblastine sulfate, vincristine sulfate, vindesinsulfate, vinorelbine, etc.), taxan anti-cancer agents (paclitaxel,docetaxel, etc.), etoposide, etoposide phosphate, teniposide andvinorelbine.

The “cell growth factors” in the said “drugs inhibiting the activity ofcell growth factors and their receptors” can be any material thatpromotes the growth of cells, and include a factor exhibiting itsactivity at low concentration by the interaction with its receptor inthe peptide of less than 20,000 molecular weight. Specifically, theyinclude (1) EGF (epidermal growth factor) or a material havingsubstantially the same activity as EGF (e.g., EGF, HER2 ligand, etc.),(2) insulin or a material having substantially the same activity asinsulin [e.g., insulin, IGF (insulin-like growth factor)-1, IGF-2,etc.], (3) FGF (fibroblast growth factor) a material havingsubstantially the same activity as FGF [e.g., acidic FGF, basic FGF, KGF(keratinocyte growth factor), FGF-10, etc.], (4) other cell growthfactors [e.g., CSF (colony stimulating factor), EPO (erythropoietin),IL-2 (interleukin-2), NGF (nerve growth factor), PDGF (platelet-derivedgrowth factor), TGFβ (transforming growth factorβ), HGF (hepatocytegrowth factor), VEGF (vascular endothelial growth factor), etc.].

The said “receptors of cell growth factors can be any receptor that hasbinding capacity with the above-mentioned cell growth factors.Specifically, they include EGF receptor, HER2, insulin receptor, IGFreceptor, FGF receptor-1 or FGF receptor-2, HGF receptor (c-met), VEGreceptor, SCF receptor (c-kit).

The said “drugs inhibiting the activity of cell growth factors” includeHerceptin (HER2 anti-body), GLEEVEC (c-met, c-kit, ab1 inhibitor),Iressa (EGF receptor inhibitor) etc.

Besides the above-mentioned drugs, topoisomerase I inhibitor (e.g.,irinotecan, topotecan, etc.), topoisomerase II inhibitor (e.g.,sobuzoxane, etc.), angiogenesis inhibitor, etc. can be used.

In the case of use of a peptide of the present invention as a preventiveand/or therapeutic drug, it may be used concomitantly with otherpreventive and/or therapeutic drug(s) for rheumatoid arthritis. Drugs ofsuch concomitant use include, for example, anti-inflammatory steroids(e.g., prednisolone, hydrocortisone, methyl-prednisolone, dexamethasone,betamethasone, etc.), nonsteroidal anti-inflammatory and analgesic drugs(e.g., indometacin, diclofenac, loxoprofen, ibuprofen, aspirin,piroxicam, sulindac, etc.) or hyaluronic acid formulations (e.g., sodiumhyaluronate, etc.), COX-II inhibitors, etc.

The peptides of the present invention exhibit an effective anti-chronicrheumatoid arthritis activity in the single preparation form, but theeffect can be further enhanced by the concomitant use (multi-drug use)together with one or more of the above-mentioned concomitant drugs.

In the concomitant use of the peptides of the present invention andconcomitant drugs, the administration time of the peptides of thepresent invention and a concomitant drug is not limited, and a peptideof the present invention and a concomitant drug can be administered tothe subject at the same time or at different times. The dose of aconcomitant drug can follow the usual dose clinically adopted, and canbe determined appropriately depending on the administration subject,administration route, disease conditions, combination, etc.

The administration mode of a peptide of the present invention and aconcomitant drug is not particularly limited, and it is acceptable if apolypeptide of the present invention or a salt thereof and a concomitantdrug are combined at the time of administration. Such administrationmode may be, for example, (1) the administration of a single preparationformulated by the simultaneous combination of a peptide of the presentinvention and a concomitant drug, (2) the simultaneous administration bythe same administration route of two different drugs—one being a drugformulated using a peptide of the present invention and the other beinga concomitant drug, (3) the administration by the same route atdifferent times of two different drugs—one being a drug formulated usinga peptide of the present invention and the other being a concomitantdrug, (4) the simultaneous administration by different routes of twodifferent drugs—one being a drug formulated using a peptide of thepresent invention and the other being a concomitant drug, (5) theadministration by different routes at different times of two differentdrugs—one being a drug formulated using a peptide of the presentinvention and the other being a concomitant drug (for example, theadministration of a peptide of the present invention followed by aconcomitant drug, or vice versa), etc. These administration modes arehereafter collectively referred to as “concomitant drug(s) of thepresent invention”.

Any concomitant drug of the present invention has low toxicity, andaccordingly, can be safely administered orally or parenterally (e.g.,local, rectum, vein, etc.) in the form of pharmaceutical compositionsprepared by mixing a peptide of the present invention and/or theabove-mentioned concomitant drug with a pharmacologically acceptablecarrier in accordance with a method known in the art. Suchpharmaceutical compositions include, without limitation, tablets(including sugar-coated tablets and film-coated tablets), powders,granules, capsules (including soft capsules), solutions, injections,suppositories, sustained-release formulations, etc. An injection can beadministered to the interior or proximal site of a tumor or directly tothe lesion by intraveneous, intramuscular, subcutaneous, intraorgan,intranasal, intradermal, eye dropping, intracerebral, intrarectal,intravaginal or intraperitoneal administration.

Pharmacogically acceptable carriers identical to those used for theabove-mentioned pharmaceutical compositions of the present invention canbe used in the manufacturing of the concomitant drugs of the presentinvention.

The combination ratio of any of the peptides of the present inventionand a concomitant drug belonging to the concomitant drugs of the presentinvention can be determined appropriately depending on the subject to beadministered, routes for administration, disease conditions, etc.

The content of a concomitant drug belonging to the concomitant drugs ofthe present invention varies depending on the drug preparation forms. Itis usually about 0.01 to 100% by weight in the whole preparation, orpreferably about 0.1 to 50% by weight, or most preferably about 0.5 to20% by weight.

The content of an additive such as a carrier in the concomitant drugs ofthe present invention varies depending on the drug preparation forms. Itis usually about 1 to 99.9% by weight in the whole preparation, orpreferably about 10 to 90% by weight.

The present invention is described in further details by the followingpractical examples, which, however, will not limit the range of thepresent invention.

MANUFACTURING EXAMPLE 1 Manufacturing of Polypeptide TC14003

H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (TC14003)

1. Synthesis of TC14003 Protected Polypeptide Resin:

After removing Fmoc group from Alko resin attached with the firstarginine of the 14-position (Fmoc-Arg(Pbf)-Alko-resin) by 20%piperidine/DMF, Fmoc-Cys(Trt)-OH (2.5 eq) of the 13-position was added,and condensation reaction by DIPCDI-HOBt method was conducted in DMF.The progress of the condensation reaction was monitered by ninhydrintest of Kaiser, E. et al. (Anal. Biochem., 34: 595 (1970)).

2. Introduction of Amino Acids of the 12-Position to 1-Position:

Similarly to the foregoing, Cit, Arg(Pbf), Tyr(t-Bu), Pro, DLys(Boc),Lys(Boc), Cit, Tyr(t-Bu), Cys(Trt), Nal, Arg(Pbf), Arg(Pbf) residueswere sequentially introduced into the resin to yield the protectedpolypeptide resin.

3. Deprotection and Clearage of Polypeptide from the Resin andPurification:

After removing Fmoc group from the protected polypeptide resin by 20%piperidine/DMF treatment, the resulting polypeptide resin was treated by1 M TMSBr-thioanisole/TFA(trifluoroacetic acid) mixture (in the presenceof m-cresol (100 eq), ethanedithiol (300 eq)) at 25° C. for 2 hours. Theresin was separated by filtration from the reaction mixture, washed withTFA twice, the mixture of the filtrate and wash solution was subjectedto concentration in vacuo, the remaining residue was added withwater-cooled dry ether, the resultant precipitation was separated fromsupernatant liquid by centrifugal sedimentation and decantation. Theobtained residue was washed with cold ether, dissolved into 1 N aceticacid, and diluted by distilled water.

4. Cyclization by Air Oxidation:

Diluted water solution of the above-mentioned polypeptide was adjustedto pH7.5 by concentrated ammonia water, and was cyclized by ventilatedair oxidation. This water solution was purified by preparative HPLC(COSMOSIL 5C18 AR-II column: acetonitrile-water) and gel filtrationchromatography (Sephadex G-15, eluate: 0.1 N AcOH), a polypeptide of asingle peak was obtained and freeze-dried. The purity was confirmed byHPLC.

MANUFACTURING EXAMPLE 2 Manufacturing of TC14005

H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH (TC14005)

TC14005 was manufactured by the same method as Manufacturing Example 1.However, DCit replaced DLys(Boc) of the 8-position and Arg(Pbf) replacedCit of the 6-position respectively during the introduction of the aminoacids from the 12-postion through the 1-position.

MANUFACTURING EXAMPLE 3 Manufacturing of TC14011

H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH (TC14011)

TC14011 was manufactured by the same method as Manufacturing Example 1.However, DCit replaced Dlys(Boc) of the 8-position during theintroduction of the amino acids from the 12-postion through the1-position.

MANUFACTURING EXAMPLE 4 Manufacturing of TC14013

H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-OH (TC14013)

TC14013 was manufactured by the same method as Manufacturing Example 1.However, Cit replaced Arg(Pbf) of the 11-position during theintroduction of the amino acids from the 12-postion through the1-position.

MANUFACTURING EXAMPLE 5 Manufacturing of TC14015

H-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (TC14015)

TC14015 was manufactured by the same method as Manufacturing Example 1.However, Cit replaced Arg(Pbf) of the 1-position during the introductionof the amino acids from the 12-postion through the 1-position.

MANUFACTURING EXAMPLE 6 Manufacturing of TC14017

H-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH (TC14017)

TC14017 was manufactured by the same method as Manufacturing Example 1.However, DCit replaced DLys(Boc) of the 8-position, Arg(Pbf) replacedCit of the 6-position and Cit replaced Arg(Pbf) of the 1-positionrespectively during the introduction of the amino acids from the12-postion through the 1-position.

MANUFACTURING EXAMPLE 7 Manufacturing of TC14019

H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-OH (TC14019)

TC14019 was manufactured by the same method as Manufacturing Example 1.However, Cit replaced Arg(Pbf) of the 11-position, DCit replacedDLys(Boc) of the 8-position, and Arg(Pbf) replaced Cit of the 6-positionduring the introduction of the amino acids from the 12-postion throughthe 1-position.

MANUFACTURING EXAMPLE 8 Manufacturing of TC14021

H-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-OH (TC14021)

TC14021 was manufactured by the same method as Manufacturing Example 1.However, Cit replaced Arg(Pbf) of the 11-position, Arg(Pbf) replaced Citof the 6-position and Cit replaced Arg(Pbf) of the 1-positionrespectively during the introduction of the amino acids from the12-postion through the 1-position.

MANUFACTURING EXAMPLE 9 Manufacturing of TC14012

H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (TC14012)

1. Synthesis of TC14012 Protected Polypeptide Resin:

After removing Fmoc group from Fmoc-Rink amide resin by 20%piperidine/DMF, Fmoc-Arg(Pbf)-OH (2.5 eq) corresponding to the14-position was added, and condensation reaction by DIPCDI-HOBt methodwas conducted in DMF. The progress of the condensation reaction wasmonitored by ninhydrin test of Kaiser, E. et al. (Anal. Biochem., 34:595 (1970)).

2. Introduction of Amino Acids of the 13-Position to 1 Position:

Similarly to the foregoing, Cys(Trt), Cit, Arg(Pbf), Tyr(t-Bu), Pro,DCit, Lys(Boc), Cit, Tyr(t-Bu), Cys(Trt), Nal, Arg(Pbf), Arg(Pbf)residues were sequentially introduced into the Rink amide resin, and theprotected polypeptide resin was obtained.

3. Deprotection and Clearage of Polypeptide from the Resin andPurification:

After removing Fmoc group from the protected polypeptide resin by 20%piperidine/DMF treatment, the resulting polypeptide resin was treated by1 M TMSBr-thioanisole/TFA(trifluoroacetic acid) mixture (in the presenceof m-cresol (100 eq), ethanedithiol (300 eq)) at 25° C. for 3 hours. Theresin was separated by filtration from the reaction mixture, washed byTFA twice, the mixture of the filtrate and the wash solution wassubjected to concentration in vacuo, the remaining residue was addedwith water-cooled dry ether, the resulting precipitation was separatedfrom supernatant liquid by centrifugal sedimentation and decantation.The obtained residue was washed with cold ether, dissolved into 1 Nacetic acid, and diluted by distilled water.

4. Cyclization by Air Oxidation:

Diluted water solution of the above-mentioned polypeptide was adjustedto pH 7.5 by concentrated ammonia water, and was cyclized by ventilatedair oxidation. This water solution was purified by preparative HPLC(COSMOSIL 5C18 AR-II column: acetonitrile-water) and gel filtrationchromatography (Sephadex G-15, eluate: 0.1 N AcOH), a polypeptide of asingle peak was obtained and freeze-dried. The purity was confirmed byHPLC.

MANUFACTURING EXAMPLE 10 Manufacturing of TC14014

H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂ (TC14014)

TC14014 was manufactured by the same method as Manufacturing Example 9.However, Cit replaced Arg(Pbf) of the 11-position and DLys(Boc) replacedDCit of the 8-position respectively during the introduction of the aminoacids from the 13-postion through the 1-position.

MANUFACTURING EXAMPLE 11 Manufacturing of TC14016

H-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (TC14016)

TC14016 was manufactured by the same method as Manufacturing Example 9.However, Dlys(Boc) replaced DCit of the 8-position and Cit replacedArg(Pbf) of the 1-position respectively during the introduction of theamino acids from the 13-postion through the 1-position.

MANUFACTURING EXAMPLE 12 Manufacturing of TC14018

H-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (TC14018)

TC14018 was manufactured by the same method as Manufacturing Example 9.However, Arg(Pbf) replaced Cit of the 6-position and Cit replacedArg(Pbf) of the 1-position respectively during the introduction of theamino acids from the 13-postion through the 1-position.

MANUFACTURING EXAMPLE 13 Manufacturing of TC14020

H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂ (TC14020)

TC14020 was manufactured by the same method as Manufacturing Example 9.However, Cit replaced Arg(Pbf) of the 11-position and Arg(Pbf) replacedCit of the 6-position respectively during the introduction of the aminoacids from the 13-postion through the 1-position.

MANUFACTURING EXAMPLE 14 Manufacturing of TC14022

H-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂ (TC14022)

TC14022 was manufactured by the same method as Manufacturing Example 9.However, Cit replaced Arg(Pbf) of the 11-position, DLys(Boc) replacedDCit of the 8-position, Arg(Pbf) replaced Cit of the 6-position and Citreplaced Arg(Pbf) of the 1-position respectively during the introductionof the amino acids from the 13-postion through the 1-position.

MANUFACTURING EXAMPLE 15 Manufacturing of TA14001, TA14005-TA14009,TC14001 and TC14004

H-Ala-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (TA14001)

H-Arg-Arg-Nal-Cys-Tyr-Ala-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (TA14005)

H-Arg-Arg-Nal-Cys-Tyr-Arg-Ala-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (TA14006)

H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DAla-Pro-Tyr-Arg-Cit-Cys-Arg-OH (TA14007)

H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Ala-Tyr-Arg-Cit-Cys-Arg-OH (TA14008)

H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Ala-Arg-Cit-Cys-Arg-OH (TA14009)

H-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (TC14001)

H-Arg-Arg-Nal-Cys-Tyr-Arg-Cit-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (TC14004)

The above-listed TA14001, TA14005-TA14009, TC14001 and TC14004 can bemanufactured by the same method as Manufacturing Example 1 or 9 withreplacements of amino acids.

MANUFACTURING EXAMPLE 16 Manufacturing of AcTC14003, AcTC14005,AcTC14011-AcTC14022

Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH(AcTC14003)

Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH(AcTC14005)

Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH(AcTC14011)

Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-OH(AcTC14013)

Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH(AcTC14015)

Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH(AcTC14017)

Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-OH(AcTC14019)

Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-OH(AcTC14021)

Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(AcTC14012)

Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂(AcTC14014)

Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(AcTC14016)

Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(AcTC14018)

Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂(AcTC14020)

Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂(AcTC14022)

Acetylated TC14003, TC14005, TC14011-TC14022 were manufactured by thesame method as Manufacturing Example 1 to 14. However, after removingFmoc group from the protected polypeptide resin by 20% piperidine/DMFtreatment, the resulting polypeptide resin was acetylated by aceticanhydride (100 eq)-pyridine (100 eq)/DMF treatment, and treated by 1MTMSBr-thioanisole/TFA(trifluoroacetic acid) mixture (in the presence ofm-cresol (100 eq), ethanedithiol (300 eq)) at 25° C. for 2 hours (incase of C-terminal being carboxylic acid) or for 3 hours (in case ofC-terminal being amide).

MANUFACTURING EXAMPLE 17 Manufacturing of Polypeptide TE14005

H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-OH (TE14005)

1. Synthesis of TE14005 Protected Polypeptide Resin:

After removing Fmoc group from Fmoc-Arg(Pbf)-Alko resin (0.74 mmol/g)270 mg (0.2 mmol) attached with the first arginine of the 14-position by20% piperidine/DMF, Fmoc-Cys(Trt)-OH (2.5 eq) corresponding to the13-position was added, and condensation reaction by DIPCDI-HOBt methodwas conducted in DMF. The progress of the condensation reaction wasmonitored by ninhydrin test of Kaiser, E. et al. (Anal. Biochem., 34:595 (1970)).

2. Introduction of Amino Acids of the 12-Position to 1 Position:

Similarly to the foregoing, Cit, Arg(Pbf), Tyr(t-Bu), Pro, DGlu(O-t-Bu),Lys(Boc), Arg(Pbf), Tyr(t-Bu), Cys(Trt), Nal, Arg(Pbf), Arg(Pbf) residuewas sequentially introduced into the resin, and protected polypeptideresin was obtained.

3. Deprotection and Clearage of Polypeptide from Resin and Purification:

After removing Fmoc group from the protected polypeptide resin (200 mg)by 20% piperidine/DMF treatment, the resulting polypeptide resin wastreated by 10 mL of 1 M TMSBr-thioanisole/TFA(trifluoroacetic acid)mixture (in the presence of m-cresol(100 eq), ethandithiol (300 eq)) at25° C. for 2 hours. The resin was separated by filtration from thereaction mixture, was washed with TFA 1 mL twice, the mixture of thefiltrate and the wash solution was subjected to concentration in vacuo,the remaining residue was added with 30 mL of water-cooled dry ether,the resultant sediment was separated from supernatant liquid bycentrifugal sedimentation and decantation. The obtained residue wascleansed by cold ether, dissolved into 50 mL of 1 N acetic acid, anddiluted to 250 mL by distilled water.

4. Cyclization by Air Oxidation:

Diluted water solution of the above-mentioned polypeptide was adjustedto pH 7.5 by concentrated ammonia water, and was cyclized by ventilatedair oxidation. This water solution was purified by preparative HPLC(COSMOSIL 5C18 AR-II column: acetonitrile water) and gel filtrationchromatography (Sephadex G-15, eluate: 0.1 N AcOH), a polypeptide of asingle peak was obtained and freeze-dried. The purity was confirmed byHPLC.

Yield: 24.1 mg (7 AcOh salt) (21.3%)

[α]D23.6=−5.36 (c 1.12, H2O)

Ionspray mass spectrum (IS-MS): C89H136N32020S2

Calculated Value: 2038.38 Actual Measurement Value: 2038

(triple stage quadrupole mass spectrometry API-IIIE (Sciex))

MANUFACTURING EXAMPLE 18 Manufacturing of Polypeptide TE14001

H-DGlu-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (TE14001)

TE14001 was manufactured by the same method as Manufacturing Example 17.However, DLys(Boc) replaced DGlu(O-t-Bu) of the 8-position, andDGlu(O-t-Bu) replaced Arg(Pbf) of the 1-position respectively during theintroduction of the amino acids from the 12-postion through the1-position.

MANUFACTURING EXAMPLE 19 Manufacturing of Polypeptide TE14002

H-Arg-Glu-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (TE14002)

TE14002 was manufactured by the same method as Manufacturing Example 17.However, DLys(Boc) replaced DGlu(O-t-Bu) of the 8-position, andGlu(O-t-Bu) replaced Arg(Pbf) of the 2-position respectively during theintroduction of the amino acids from the 12-postion through the1-position.

MANUFACTURING EXAMPLE 20 Manufacturing of Polypeptide TC14003

H-Arg-Arg-Nal-Cys-Tyr-Glu-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (TE14003)

TE14003 was manufactured by the same method as Manufacturing Example 17.However, DLys(Boc) replaced DGlu(O-t-Bu) of the 8-position, andDGlu(O-t-Bu) replaced Arg(Pbf) of the 6-position respectively during theintroduction of the amino acids from the 12-postion through the1-position.

MANUFACTURING EXAMPLE 21 Manufacturing of Polypeptide TE14004

H-Arg-Arg-Nal-Cys-Tyr-Arg-Glu-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (TE14004)

TE14004 was manufactured by the same method as Manufacturing Example 17.However, Dlys(Boc) replaced DGlu(O-t-Bu) of the 8-position, andDGlu(O-t-Bu) replaced Lys(Boc) of the 7-position respectively during theintroduction of the amino acids from the 12-postion through the1-position.

MANUFACTURING EXAMPLE 22 Manufacturing of Polypeptide TE14006

H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Glu-Cit-Cys-Arg-OH (TE14006)

TE14006 was manufactured by the same method as Manufacturing Example 17.However, DLys (Boc) replaced DGlu(O-t-Bu) of the 8-position, andDGlu(O-t-Bu) replaced Arg(Pbf) of the 11-position respectively duringthe introduction of the amino acids from the 12-postion through the1-position.

MANUFACTURING EXAMPLE 23 Manufacturing of Polypeptide TE14007

H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Glu-OH (TE14007)

TE14007 was manufactured by the same method as Manufacturing Example 17.However, instead of Fmoc-Arg(Pbf)-Alko resin attached with the firstarginine of the 14-position, Fmoc-Glu(O-t-Bu)-Alko resin attached withglutamic acid of the 14-position was used, and also, DLys(Boc) replacedDGlu(O-t-Bu) of the 8-position during the introduction of the aminoacids from the 12-postion through the 1-position.

MANUFACTURING EXAMPLE 24 Manufacturing of Polypeptide TE14011

H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (TE14011)

1. Synthesis of TE14011 Protected Polypeptide Resin:

After removing Fmoc group from Fmoc-Rink amide resin by 20%piperidine/DMF, Fmoc-Arg(Pbf)-OH (2.5 eq) corresponding to the14-position was added, and condensation reaction by DIPCDI-HOBt methodwas conducted in DMF. The progress of the condensation reaction wasmonitored by ninhydrin test of Kaiser, E. et al. (Anal. Biochem. 34: 595(1970)).

2. Introduction of Amino Acids of the 13-Position to the 1-Position:

Similarly to the foregoing, Cys(Trt), Cit, Arg(Pbf), Tyr(t-Bu), Pro,DGlu(O-t-Bu), Lys(Boc), Cit, Tyr(t-Bu), Cys(Trt), Nal, Arg(Pbf),Arg(Pbf) residue was sequentially introduced into the Rink amide resin,and the protected polypeptide resin was obtained.

3. Deprotection and Cleavage of Polypeptide from Resin and Purification:

After removing Fmoc group from the protected polypeptide resin by 20%piperidine/DMF treatment, the resulting polypeptide resin was treated by1 M TMSBr-thioanisole/TFA(trifluoroacetic acid) mixture (in the presenceof m-cresol (100 eq), ethanedithiol (300 eq)) at 25° C. for 3 hours. Theresin was separated by filtration from the reaction mixture, washed withTFA twice, the mixture of the filtrate and the wash solution wassubjected to concentration in vacuo, the remaining residue was addedwith water-cooled dry ether, the resulting precipitation was separatedfrom supernatant liquid by centrifugal sedimentation and decantation.The obtained residue was cleansed by cold ether, dissolved into 1 Nacetic acid, and diluted by distilled water.

4. Cyclization by Air Oxidation:

Diluted water solution of the above-mentioned polypeptide was adjustedto pH 7.5 by concentrated ammonia water, and was cyclized by ventilatedair oxidation. This water solution was purified by preparative HPLC(COSMOSIL 5C18 AR-II column: acetonitrile water) and gel filtrationchromatography (Sephadex G-15, eluate: 0.1N AcOH), a polypeptide of asingle peak was obtained and freeze-dried. The purity was confirmed byHPLC.

MANUFACTURING EXAMPLE 25 Manufacturing of Polypeptide TE14012

H-Arg-Arg-Nal-Cys-Tyr-DGlu-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(TE14012)

TE14012 was manufactured by the same method as Manufacturing Example 24.However, DCit replaced DGlu(O-t-Bu) of the 8-position, and DGlu(O-t-Bu)replaced Cit of the 6-position respectively during the introduction ofthe amino acids from the 13-postion through the 1-position.

MANUFACTURING EXAMPLE 26 Manufacturing of Polypeptide TE14013

H-Arg-Arg-Nal-Cys-Tyr-DGlu-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(TE14013)

TE14013 was manufactured by the same method as Manufacturing Example 24.However, DGlu(O-t-Bu) replaced Cit of the 6-position during theintroduction of the amino acids from the 13-postion through the1-position.

MANUFACTURING EXAMPLE 27 Manufacturing of Polypeptide TE14014

H-DGlu-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(TE14014)

TE14014 was manufactured by the same method as Manufacturing Example 24.However, DGlu(O-t-Bu) replaced Arg(Pbf) of the 1-position during theintroduction of the amino acids from the 13-postion through the1-position.

MANUFACTURING EXAMPLE 28 Manufacturing of Polypeptide TE14015

H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-DGlu-Arg-Cit-Cys-Arg-NH₂(TE14015)

TE14015 was manufactured by the same method as Manufacturing Example 24.However, DGlu(O-t-Bu) replaced Tyr(t-Bu) of the 10-position during theintroduction of the amino acids from the 13-postion through the1-position.

MANUFACTURING EXAMPLE 29 Manufacturing of Polypeptide TE14016

H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-DGlu-Cys-Arg-NH₂(TE14016)

TE14016 was manufactured by the same method as Manufacturing Example 24.However, DGlu(O-t-Bu) replaced Cit of the 12-position during theintroduction of the amino acids from the 13-postion through the1-position.

MANUFACTURING EXAMPLE 30 Manufacturing of PolypeptideAcTE14014-AcTE14016

Ac-DGlu-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(AcTE14014)

Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-DGlu-Arg-Cit-Cys-Arg-NH₂(AcTE14015)

Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-DGlu-Cys-Arg-NH₂(AcTE14016)

Acetylated TE14014-TE14016 were manufactured by the same method asManufacturing Example 27-29. However, after removing Fmoc group from theprotected polypeptide resin by 20% piperidine/DMF treatment, theresulting polypeptide resin was acetylated by acetic anhydride (100eq)-pyridine (100 eq)/DMF treatment, and treated by 1 MTMSBr-thioanisole/TFA(trifluoroacetic acid) mixture (in the presence ofm-cresol (100 eq), ethanedithiol (300 eq)) at 25° C. for 3 hours.

MANUFACTURING EXAMPLE 31 Manufacturing of Polypeptide TF1

Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (TF1:AcTE14011)

TF1 was manufactured by the same method as Manufacturing Example 24.

However, after removing Fmoc group from the protected polypeptide resinby 20% piperidine/DMF treatment, the resulting polypeptide resin wasacetylated by acetic anhydride (100 eq)-pyridine (100 eq)/DMF treatment,and treated by 1 M TMSBr-thioanisole/TFA(trifluoroacetic acid) mixture(in the presence of m-cresol (100 eq), ethanedithiol (300 eq)) at 25° C.for 2 hours (in case of C-terminal being carboxylic acid) or for 3 hours(in case of C-terminal being amide).

MANUFACTURING EXAMPLE 32 Manufacturing of Polypeptide TF2

guanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(TF2: guanyl-TE14011)

TF2 was manufactured by the same method as Manufacturing Example 24.

However, after removing Fmoc group from the protected polypeptide resinby 20% piperidine/DMF treatment, the resulting polypeptide resin wasguanylated by 1H-pyrazole-1-carboxamidine (5eq)-N,N-diisopropylethylamine (10 eq)/DMF treatment, and treated by 1MTMSBr-thioanisole/TFA(trifluoroacetic acid) mixture (in the presence ofm-cresol (100 eq), ethandithiol (300 eq)) at 25° C. for 3 hours.

MANUFACTURING EXAMPLE 33 Manufacturing of Polypeptide TF3

TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(TF3: TMguanyl-TE14011)

TF3 was manufactured by the same method as Manufacturing Example 24.

However, after removing Fmoc group from the protected polypeptide resinby 20% piperidine/DMF treatment, the resulting polypeptide resin wastetramethylguanylated by2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate(5 eq)/DMF treatment, and treated with 1 MTMSBr-thioanisole/TFA(trifluoroacetic acid) mixture (in the presence ofm-cresol (100 eq), ethanedithiol (300 eq)) at 25° C. for 3 hours.

MANUFACTURING EXAMPLE 34 Manufacturing of Polypeptide TF4

TMguanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (TF4:TMguanyl-TE14011 (2-14))

TF4 was manufactured by the same method as Manufacturing Example 24.

However, arginine of the 1-position was not condensed.

MANUFACTURING EXAMPLE 35 Manufacturing of Polypeptide TF5

4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(TF5: 4F-benzoyl-TE14011)

TF5 was manufactured by the same method as Manufacturing Example 24.

However, after removing Fmoc group from the protected polypeptide resinby 20% piperidine/DMF treatment, the resulting polypeptide resin wascondensed with 4-fluorobenzoic acid (2.5 eq) by DIPCDI-HOBt method, andtreated with 1 M TMSBr-thioanisole/TFA(trifluoroacetic acid) mixture (inthe presence of m-cresol (100 eq), ethanedithiol (300 eq)) at 25° C. for3 hours.

MANUFACTURING EXAMPLE 36 Manufacturing of Polypeptide TF6

2F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(TF6: 2F-benzoyl-TE 14011)

TF6 was manufactured by the same method as Manufacturing Example 24.

However, after removing Fmoc group from the polypeptide resin protectedby protecting group by 20% piperidine/DMF treatment, the resultingpolypeptide resin was condensed with 2-fluorobenzoic acid (2.5 eq) byDIPCDI-HOBt method, and treated with 1MTMSBr-thioanisole/TFA(trifluoroacetic acid) mixture (in the presence ofm-cresol (100 eq), ethandithiol (300 eq)) at 25° C. for 3 hours.

MANUFACTURING EXAMPLE 37 Manufacturing of Polypeptide TF7

APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (TF7:APA-TE14011 (2-14))

TF7 was manufactured by the same method as Manufacturing Example 24.

However, instead of Arg(Pbf) of the 1-position, Fmoc-aminopentanoic acidwas introduced after the introduction of the amino acids from the13-postion through the 1-position.

MANUFACTURING EXAMPLE 38 Manufacturing of Polypeptide TF8

desamino-R-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(TF8: desamino-R-TE14011 (2-14))

TF8 was manufactured by the same method as Manufacturing Example 24.

However, instead of Arg(Pbf) of the 1-position, Fmoc-5-aminopentanicacid was introduced after the introduction of the amino acids from the13-postion through the 1-position.

Furthermore, after removing Fmoc group from the protected polypeptideresin by 20% piperidine/DMF treatment, the resulting polypeptide resinwas guanylated by 1H-pyrazole-1-carboxamidine (5 eq)/DMF treatment, andtreated by 1 M TMSBr-thioanisole/TFA(trifluoroacetic acid) mixture (inthe presence of m-cresol (100 eq), ethanedithiol (300 eq)) at 25° C. for3 hours.

MANUFACTURING EXAMPLE 39 Manufacturing of Polypeptide TF9

guanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (TF9:guanyl-TE14011 (2-14))

TF9 was manufactured by the same method as Manufacturing Example 32.

However, arginine of the 1-position was not condensed.

Furthermore, after removing Fmoc group from the protected polypeptideresin by 20% piperidine/DMF treatment, the resulting polypeptide resinwas guanylated by 1H-pyrazole-1-carboxamidine (5 eq)/DMF treatment, andtreated by 1 M TMSBr-thioanisole/TFA(trifluoroacetic acid) mixture (inthe presence of m-cresol (100 eq), ethanedithiol (300 eq)) at 25° C. for3 hours.

MANUFACTURING EXAMPLE 40 Manufacturing of Polypeptide TF10

succinyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (TF10:succinyl-TE14011 (2-14))

TF10 was manufactured by the same method as Manufacturing Example 24.

However, arginine of the 1-position was not condensed.

Also, after removing Fmoc group from the protected polypeptide resin by20% piperidine/DMF treatment, the resulting polypeptide resin washemisuccinylated by succinic anhydride (5 eq)/pyridine treatment, andtreated by 1 M TMSBr-thioanisole/TFA(trifluoroacetic acid) mixture (inthe presence of m-cresol (100 eq), ethanedithiol (300 eq)) at 25° C. for3 hours.

MANUFACTURING EXAMPLE 41 Manufacturing of Polypeptide TF11

glutaryl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (TF11:glutaryl-TE14011 (2-14))

TF11 was manufactured by the same method as Manufacturing Example 40.

However, after removing Fmoc group from the protected polypeptide resinby 20% piperidine/DMF treatment, the resulting polypeptide resin washemiglutarylated by glutaric anhydride (5 eq)/pyridine treatment, andtreated by 1 M TMSBr-thioanisole/TFA(trifluoroacetic acid) mixture (inthe presence of m-cresol (100 eq), ethanedithiol (300 eq)) at 25° C. for3 hours.

MANUFACTURING EXAMPLE 42 Manufacturing of Polypeptide TF12

deaminoTMG-APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(TF12: deaminoTMG-APA-TE14011 (2-14))

TF12 was manufactured by the same method as Manufacturing Example 24.

However, instead of Arg(Pbf) of the I-position, Fmoc-5-aminopentanoicacid was introduced after the introduction of the amino acids from the13-postion through the 1-position.

Furthermore, after removing Fmoc group from the protected polypeptideresin by 20% piperidine/DMF treatment, the resulting polypeptide resinwas tetramethylguanylated by2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate(5 eq)/DMF treatment, and treated by 1 MTMSBr-thioanisole/TFA(trifluoroacetic acid) mixture (in the presence ofm-cresol (100 eq), ethanedithiol (300 eq)) at 25° C. for 3 hours.

MANUFACTURING EXAMPLE 43 Manufacturing of Polypeptide TF15

R—CH2-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (TF15:R—CH2NH-RTE14011)

TF15 was manufactured by the same method as Manufacturing Example 24.

However, at the I-position, Fmoc-Arg(Pbf)-H (aldehyde) was condensed byreductive amidation (NaB(CN)H3 (3 eq), AcOH (1 eq)/DMF) instead of thecondensation of Fmoc-Arg(Pbf)-OH after the introduction of the aminoacids from the 13-postion through the 2-position.

MANUFACTURING EXAMPLE 44 Manufacturing of Polypeptide TF17

H-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (TF17) (TF17:TE14011 (2-14))

TF17 was manufactured by the same method as Manufacturing Example 24.

However, arginine of the 1-position was not condensed.

MANUFACTURING EXAMPLE 45 Manufacturing of Polypeptide TF18

TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(TF18: TMguanyl-TC14012)

TF18 was manufactured by the same method as Manufacturing Example 9.

However, after removing Fmoc group from the protected polypeptide resinby 20% piperidine/DMF treatment, the resulting polypeptide resin wastetramethylguanylated by2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate(5 eq)/DMF treatment, and treated by 1 M TMSBr-thioanisole/TFA(trifluoroacetic acid) mixture (in the presence of m-cresol (100 eq),ethanedithiol (300 eq)) at 25° C. for 3 hours.

MANUFACTURING EXAMPLE 46 Manufacturing of Polypeptide TF19

ACA-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (TF19:ACA-TC14012)

TF19 was manufactured by the same method as Manufacturing Example 9.

However, next to Arg(Pbf) of the 1-position, Fmoc-6-aminohexanoic acidwas introduced after the introduction of the amino acids from the13-postion through the 1-position.

MANUFACTURING EXAMPLE 47 Manufacturing of Polypeptide TF20

ACA-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (TF20:ACA-T140)

TF20 was manufactured by the same method as Manufacturing Example 17.

However, DLys(Boc) replaced DGlu(O-t-Bu) of the 8-position, andFmoc-6-aminohexanoic acid replaced Arg (Pbf) of the 1-positionrespectively after the introduction of the amino acids from the12-postion through the 1-position.

MANUFACTURING EXAMPLE 48 Manufacturing of Polypeptide TZ14011

H-Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (TZ14011)

TZ14011 was manufactured by the same method as Manufacturing Example 24.

However, DLys(Boc) replaced DGlu(O-t-Bu) of the 8-position, and Arg(Pbf) replaced Lys (Boc) of the 7-position respectively during theintroduction of the amino acids from the 13-postion through theI-position.

MANUFACTURING EXAMPLE 49 Manufacturing of Polypeptide AcTZ14011

Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(AcTZ14011)

AcTZ14011 was manufactured by the same method as Manufacturing Example48. However, after removing Fmoc group from the protected polypeptideresin by 20% piperidine/DMF treatment, the resulting polypeptide resinwas acetylated by acetic anhydride (100 eq)-pyridine (100 eq)/DMFtreatment, and treated by 1M TMSBr-thioanisole/TFA(trifluoroacetic acid)mixture (in the presence of m-cresol (100 eq), ethanedithiol (300 eq))at 25° C. for 3 hours.

MANUFACTURING EXAMPLE 50 Manufacturing of Polypeptide TN14003

H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (TN14003)

TN14003 was manufactured by the same method as Manufacturing Example 9.However, DLys(Boc) replaced DCit of the 8-position during theintroduction of the amino acids from the 13-postion through the1-position.

MANUFACTURING EXAMPLE 51 Manufacturing of Polypeptide TN14005

H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (TN14005)

TN14005 was manufactured by the same method as Manufacturing Example 9.However, Arg(Pbf) replaced Cit of the 6-position during the introductionof the amino acids from the 13-postion through the 1-position.

MANUFACTURING EXAMPLE 52 Manufacturing of Polypeptide AcTN14003

Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(AcTN14003)

AcTN14003 was manufactured by the same method as Manufacturing Example50. However, after removing Fmoc group from the protected polypeptideresin by 20% piperidine/DMF treatment, the resulting polypeptide resinwas acetylated by acetic anhydride (100 eq)-pyridine (100 eq)/DMFtreatment, and treated by 1 M TMSBr-thioanisole/TFA(trifluoroaceticacid) mixture (in the presence of m-cresol (100 eq), ethanedithiol (300eq)) at 25° C. for 3 hours.

MANUFACTURING EXAMPLE 53 Manufacturing of Polypeptide AcTN14005

Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(AcTN14005)

AcTN14005 was manufactured by the same method as Manufacturing Example51. However, after removing Fmoc group from the protected polypeptideresin by 20% piperidine/DMF treatment, the resulting polypeptide resinwas acetylated by acetic anhydride (100 eq)-pyridine (100 eq)/DMFtreatment, and treated by 1 M TMSBr-thioanisole/TFA(trifluoroaceticacid) mixture (in the presence of m-cresol (100 eq), ethanedithiol (300eq)) at 25° C. for 3 hours.

MANUFACTURING EXAMPLE 54 Manufacturing of Polypeptide 4F-benzoyl-TN14003

4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(4F-benzoyl-TN14003)

1. Synthesis of 4F-benzoyl-TN14003 Protected Polypeptide Resin:

After removing Fmoc group from Fmoc-Rink amide resin (0.34 mmol/g) 2.94g (1 mmol) by 20% piperidine/DMF, Fmoc-Arg(Pbf)-OH (2.5 eq)corresponding to the 14-position was added, and condensation reaction byDIPCDI-HOBt method was conducted in DMF. The progress of thecondensation reaction was monitored by ninhydrin test of Kaiser, E. etal. (Anal. Biochem. 34: 595 (1970)).

2. Introduction of Amino Acids of the 13-Position to 1 Position:

Similarly to the foregoing, Cys(Trt), Cit, Arg(Pbf), Tyr(t-Bu), Pro,DLys(Boc), Lys(Boc), Cit, Tyr(t-Bu), Cys(Trt), Nal, Arg(Pbf), Arg(Pbf)residue was sequentially introduced into Rink amide resin,4-fluorobenzoic acid (2.5 eq) was condensed at the last N-terminal byDIPCDI-HOBt method and the protected polypeptide resin was obtained.

3. Deprotection and Clearage of Polypeptide from Resin and Purification:

The protected polypeptide resin(1 mmol) was treated by 270 mL of 1 MTMSBr-thioanisole/TFA(trifluoroacetic acid) mixture (in the presence ofm-cresol (100 eq), ethanedithiol (300 eq)) at 25° C. for 3 hours. Theresin was separated by filtration from the reaction mixture, washed withTFA 5 mL twice, the mixture of the filtrate and the wash solution wassubjected to concentration in vacuo. The remaining residue was addedwith 300 mL of water-cooled dry ether, the resultant sediment wasseparated from supernatant liquid by centrifugal sedimentation anddecantation. The obtained residue was cleansed by cold ether, dissolvedinto 500 mL of 1 N acetic acid, and diluted to 2.5 L by distilled water.

4. Cyclization by Air Oxidation:

Diluted water solution of the above-mentioned polypeptide was adjustedto pH 7.5 by concentrated ammonia water, and was cyclized by ventilatedair oxidation. This water solution was purified by preparative HPLC(COSMOSIL 5C 18 AR-II column: acetonitrile water) and gel filtrationchromatography (Sephadex G-15, eluate: 0.1 N AcOH), a polypeptide of asingle peak was obtained and freeze-dried. The purity was confirmed byHPLC.

Yield: 551.5 mg (6 TFA salt) (19.4%)

[α]D28.6=−10.25 (c 0.39, H2O)

Ionspray mass spectrum (IS-MS): C97H144FN33019S2

Calculated Value: 2159.52 Actual Measurement Value: 2161

(triple stage quadrupole mass spectrometry API-IIIE (Sciex))

MANUFACTURING EXAMPLE 55 Manufacturing of Polypeptide4F-benzoyl-TE14011-Me

4-fluorobenzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHMe(4F-benzoyl-TE 14011-Me)

1. Synthesis of 4F-benzoyl-TE14011-Me Protected Polypeptide Resin:

4-sulfamylbutyryl AM NovaGel resin was added with. Fmoc-Arg(Pbf)-OH (4eq) corresponding to the 14-position, and, in CHCl3, condensationreaction by PyBOP (3 eq)-DIPEA (6 eq) method was conducted at 0° C.(This condensation reaction was repeated twice). After removing Fmocgroup by 20% piperidine/DMF, Fmoc-Cys(Trt)-OH (2.5 eq) corresponding tothe 13-position was added, and condensation reaction by DIPCDI-HOBtmethod was conducted in DMF. The degree of the progress of thecondensation reaction was monitored by ninhydrin test of Kaiser, E. etal. (Anal. Biochem., 34: 595 (1970)).

Similarly to the foregoing for the introduction of amino acids from the12-position to the I-position, Cit, Arg(Pbf), Tyr(t-Bu), Pro,DGlu(O-t-Bu), Lys(Boc), Cit, Tyr(t-Bu), Cys(Trt), Nal, Arg(Pbf),Arg(Pbf) residue was sequentially introduced into the sulfamylbutyrylresin, 4-fluorobenzoic acid (2.5 eq) was condensed at the lastN-terminal by DIPCDI-HOBt method to yield the protected polypeptideresin.

2. C-Terminal Alkylamidation, Deprotection and Clearage of Polypeptidefrom Resin and Purification:

The protected polypeptide resin was cyanomethylated by ICH2CN (40 eq),DIPEA (10 eq)/NMP treatment (48 hours), then, treated by methylamine(excess) in THF/DMF, and the protected C-terminally methylamidatedpolypeptide was isolated from the resin. The protected polypeptide wastreated by 1 M TMSBr-thioanisole/TFA(trifluoroacetic acid) mixture (inthe presence of m-cresol (100 eq), ethanedithiol (300 eq)) at 25° C. for3 hours. The reaction solution was subjected to concentration in vacuo,the remaining residue was added with water-cooled dry ether, theresultant sediment was separated from supernatant liquid by centrifugalsedimentation and decantation. The obtained residue was cleansed by coldether, dissolved into 1N acetic acid, and diluted by distilled water.

3. Cyclization by Air Oxidation:

Diluted water solution of the above-mentioned polypeptide was adjustedto pH 7.5 by concentrated ammonia water, and was cyclized by ventilatedair oxidation. This water solution was purified by preparative HPLC(COSMOSIL 5C18 AR-II column: acetonitrile water) and gel filtrationchromatography (Sephadex G-15, eluate: 0.1 N AcOH), a polypeptide of asingle peak was obtained and freeze-dried. The purity was confirmed byHPLC.

MANUFACTURING EXAMPLE 56 Manufacturing of Polypeptide4F-benzoyl-TE14011-Et

4-fluorobenzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHEt(4F-benzoyl-TE 14011-Et)

4F-benzoyl-TE14011-Et was manufactured by the same method asManufacturing Example 55. However, ethylamine replaced methylamine.

MANUFACTURING EXAMPLE 57 Manufacturing of Polypeptide4F-benzoyl-TE14011-iPr

4-fluorobenzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHiPr

(4F-benzoyl-TE 14011-iPr)

4F-benzoyl-TE14011-iPr was manufactured by the same method asManufacturing Example 55. However, isopropylamine replaced methylamine.

MANUFACTURING EXAMPLE 58 Manufacturing of Polypeptide4F-benzoyl-TE14011-tyramine

4-fluorobenzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-tyramine

(4F-benzoyl-TE 14011-tyramine)

4F-benzoyl-TE14011-tyramine was manufactured by the same method asManufacturing Example 55. However, tyramine(p-hydroxyphenylethylamine)replaced methylamine.

EXPERIMENTAL EXAMPLE 1 The Inhibitory Activity of the Peptides of thePresent Invention Against CXCL12 Binding to CXCR4 Receptor

50 μL of Jurkat human T-cell leukemia cells (6×10⁶ cells/mL) suspendedin buffer (Dulbecco's PBS solution (pH 7.0) containing 0.5% BSA, 20 mMHEPES), 25 μL of test compounds (Table 1: each compound beingsynthesized in the form of acetate salt) diluted by buffer and 25 μL of200 pM 125I-CXCL12 solution were respectively dispensed to each well ofthe plate, and were subjected to fixation reaction for 1 hour at roomtemperature. After reaction, suction was made toward the reactionsolution by 96 well GF/C filter plate, and each well's radioactivity wasmeasured by top count. As the radioactivity index of 100% when the testcompound was not added, and 0% when 100 nM of non-radioisotope-labeledCXCL12 was added, the inhibitory activity of each test compound wasmeasured. The result is indicated in the following Table 1. No. IC50(nM) TE14002 680 TE14003 5 TE14004 6.8 TE14005 2.2 TE14006 5.6 TE140112.9 TE14012 5.4 TE14013 9.3 4F-benzoyl-TN14003 0.99 TF1 11 TF2 3.3 TF39.6 TF4 9.9 TF5 2.8 TF6 3.9 TF7 5.7 TF8 8.2 TF9 250 TF10 48 TF11 630TF12 4.6 TF13 21 TF14 49 TF15 95 TF17 79 TF18 8 TF19 4.5 TF20 3.5

The results indicated in Table 1 shows that the compounds have potentbinding inhibitory activity.

EXPERIMENTAL EXAMPLE 2 The Inhibitory Activity of TE-14005 AgainstBreast Cancer Cell Migration Induced by CXCL12

Transwell filter (polycarbonate filter, 8 μm diameter, Costar Company)was treated at 37° C. for 6 hours in 10 μg/mL fibronectin solution andair-dried. 100 nM of CXCL12 (R&D System Company) and 600 μL/well ofbuffer-A (0.1% bovine serum albumin, DMEM (GibcoBRL) containing 12 mMHEPES) containing the test compound were added to the lower chamber ofthe Transwell. The test compound and human breast cancer MDA-MB-231cells (purchased from American Tissue Culture Collection), and 100μL/well of buffer A containing 2×10⁶ cells/mL were added to the upperchamber. After 15 hours' incubation at 37° C. in 5% CO₂ incubator, theupper surface of the filter was wiped and the cell was removed, and thenthe cell on the lower surface of the filter was fixed and stained with25% methanol solution containing 0.5% crystal violet (Wako Pure ChemicalInd.), washed by distilled water and air-dried. Cutting off the filterpart, adding 0.1 M sodium citrate/50% ethanol solution, and elutingcrystal violet absorption at 550 nm was measured. The result isindicated in FIG. 1. Control (−) indicates the migration when CXCL12 wasnot added. By adding CXCL12, the migration of MDA-MB-231 cells wasenhanced. This CXCL12-induced migration of MDA-MB-231 cells wasinhibited by 10 nM of the antagonist, TE14005.

EXPERIMENTAL EXAMPLE 3 The Inhibitory Activity of TC14012 and TN14003Against CXCL12 Binding to CXCR4 Receptor

50 μL of Jurkat human T-cell leukemia cells (6×10⁶ cells/mL) suspendedin buffer (Dulbecco's PBS solution (pH 7.0) containing 0.5% BSA, 20 mMHEPES), 25 μL of test compounds (Table 2: each compound beingsynthesized in the form of acetate salt) diluted by buffer and 25 μL of200 p M 125I-CXCL12 solution were respectively dispensed to each well ofthe plate, and were subjected to fixation reaction for 1 hour at roomtemperature. After reaction, suction was made toward the reactionsolution by 96 well GF/C filter plate, and each well's radioactivity wasmeasured by top count. As the radioactivity index of 100% when the testcompound was not added, and 0% when 100 nM of non-radioisotope-labeledCXCL12 was added, the inhibitory activity of each test compound wasmeasured. The result is indicated in the following Table 2. No. IC50(nM) TC14012 2.7 TN14003 2.6

The result indicated in Table 2 shows that the compounds have potentbinding inhibitory activity.

EXPERIMENTAL EXAMPLE 4 The Inhibitory Activity of TC-14012 AgainstBreast Cancer Cell Migration Induced by CXCL12

Transwell filter (polycarbonate filter, 8 μm diameter, Costar Company)was treated at 37° C. for 6 hours in 10 μg/mL fibronectin solution andair-dried. 100 nM of CXCL12 (R&D System Company) and 600 μL/well ofbuffer-A (0.1% bovine serum albumin, DMEM (GibcoBRL) containing 12 mMHEPES) containing the test compound were added to the lower chamber ofthe Transwell. The test compound and human breast cancer MDA-MB-231cells (purchased from American Tissue Culture Collection), and 100μL/well of buffer A containing 2×10⁶ cells/mL were added to the upperchamber. After 15 hours' incubation at 37° C. in 5% CO₂ incubator, theupper surface of the filter was wiped and the cell was removed, and thenthe cell on the lower surface of the filter was fixed and stained with25% methanol solution containing 0.5% crystal violet (Wako Pure ChemicalInd.), washed by distilled water and air-dried. Cutting off the filterpart, adding 0.1 M sodium citrate/50% ethanol solution, and elutingcrystal violet absorption at 550 nm was measured. The result isindicated in FIG. 2. Control (−) indicates the migration when CXCL12 wasnot added. By adding CXCL12, the migration of MDA-MB-231 cells wasenhanced. This CXCL12-induced migration of MDA-MB-231 cells wasinhibited by 10 nM of the antagonist, TE14005.

EXPERIMENTAL EXAMPLE 5 The Inhibitory Activity of 4Fbenzoyl-TN-14003Against T-Cell Derived Leukemia Cell Migration Induced by CXCL12

30 nM of CXCL12 (R&D System Company) and 600 μL/well of buffer-A (0.1%bovine serum albumin, DMEM (GibcoBRL) containing 12 mM HEPES) containingthe test compound were added to the lower chamber of Transwell filter(polycarbonate filter, 8 μm diameter, Costar Company). The test compoundand human cell-derived leukemia SUP-T1 cells (purchased from AmericanTissue Culture Collection), and 100 μL/well of buffer A containing 2×10⁶cells/mL were added to the upper chamber.

After 4 hours' incubation at 37° C. in 5% CO₂ incubator, the number ofthe cells moved to the lower chamber was counted by Coulter counter. Theresult is indicated in FIG. 3. Control (−) indicates the migration whenCXCL12 was not added. Control (+) indicates the migration when CXCL12was added. By adding CXCL12, the migration of SUP-T1 cells was enhanced.This CXCL12-induced migration of SUP-T1 cells was inhibited by 10 nM ofthe antagonist, 4Fbenzoyl-TN-14003. From the foregoing,4Fbenzoyl-TN-14003, by inhibiting the movement of T-cells at lowconcentrations, is considered to be useful as an inhibitory drug forchronic rheumatoid arthritis.

EXPERIMENTAL EXAMPLE 6 The Inhibitory Activity of 4Fbenzoyl-TN-14003Against Breast Cancer Cell Migration Induced by CXCL12

Transwell filter (polycarbonate filter, 8 μm diameter, Costar Company)was treated at 37° C. overnight in 10 mg/mL fibronectin solution andair-dried. 100 nM of CXCL12 (R&D System Company) and 600 μL/well ofbuffer-A (0.1% bovine serum albumin, DMEM (GibcoBRL) containing 12 mMHEPES) containing 4Fbenzoyl-TN-14003 were added to the lower chamber ofTranswell. 4Fbenzoyl-TN-14003 and human breast cancer MDA-MB-231 cells(purchased from American Tissue Culture Collection), and 100 μL/well ofbuffer A containing 2×10⁶ cells/mL were added to the upper chamber. Thetest compound and human breast cancer MDA-MB-231 cells (purchased fromAmerican Tissue Culture Collection), and 100 mL/well of buffer Acontaining 2×10⁶ cells/mL were added to the upper chamber. After 15hours' incubation at 37° C. in 5% CO₂ incubator, the upper surface ofthe filter was wiped and the cell was removed, and then the cell on thelower surface of the filter was fixed and stained with 25% methanolsolution containing 0.5% crystal violet (Wako Pure Chemical Ind.),washed by distilled water and air-dried. Cutting off the filter part,adding 0.1 M sodium citrate/50% ethanol solution, and eluting crystalviolet absorption at 550 nm was measured. The result is indicated inFIG. 4. Control (−) indicates the migration when CXCL12 was not added.Control (+) indicates the migration when CXCL12 was added. By addingCXCL12, the migration of MDA-MB-231 cells was enhanced. ThisCXCL12-induced migration of MDA-MB-231 cells was inhibited by 10 nM ofthe antagonist, 4Fbenzoyl-TN-14003.

EXPERIMENTAL EXAMPLE 7 Anti-Metastatic Activity of 4Fbenzoyl-TN-14003

MDA-MB-231 human breast cancer cells (10⁶ cells) were implantedintravenously into the tails of five week-old female CB-17 SCID mice(Crea Japan, Inc.). 4Fbenzoyl-TN-14003 was prepared at 80 mg/mL inphysiologic saline solution, was included into sustained-releasingosmotic pumps (Alzet pump, Alza Corporation, usable for 2 weeksustained-release; the dose was equivalent to 18.2 mg/kg/day), and wasintradermally loaded to the backs of the mice on the date immediatelypreceding the implantation. Further, 14 days after the implantation,Alzet pumps containing an equal dose of the drug were additionallyloaded. To the control group, Alzet pumps injected with physiologicalsaline solution were additionally loaded. 28 days after theimplantation, the mice were dissected, about 2 mL of 0.2% Evans' Bluesolution was injected through windpipes, and lungs were stained. Thelungs were taken out, soaked in Bouin's liquid, stained and fixed. Byeye observation of metastatic focus (yellow stained potion), theevaluation was conducted to determine whether or not the compoundexhibited more evident anti-metastatic activity. The result is indicatedin FIG. 5. In the lungs of the control group, the yellow stainedportions were evenly seen, and lung metastasis was observed. On theother hand, in the 4Fbenzoyl-TN-14003 administration group, yellowstained specimens were less. Comperatively, the metastasis was inhibitedby 4Fbenzoyl-TN-14003.

EXPERIMENTAL EXAMPLE 8 The Inhibitory Activity of 4Fbenzoyl-TN-14003Against CXCL12-Induced Migration of Human Cell Lines (Jurkat) and MouseSplenocytes

1. Effects on the Migrating Reaction of Human T-Cell Lines:

RPMI-1640 and fetal calf serum (FCS) was purchased from BioWhittaker,penicillin-streptomycin solution, RPMI-1640 (without phenol red) andHEPES from Invitrogen, BSA from Sigma, and, human SDF-1α (CXCL12) fromGenzyme. Jurkat human T lymphocyte cell lines were purchased from ATCCand incubated in RPMI-1640 10% FCS. 4Fbenzoyl-TN14003 was dissolved toPBS and used for experiments.

Using 24-wells Transwell (Costar, polycarbonate membrane, pore size 5μm), migrating reaction was performed. 600 μL of SDF-1α (finalconcentration 1 ng/mL) was added to the lower layer of Transwell, 5×10⁵cells (200 mL) was added to the insert, and was reacted at 37° C. for 4hours. The cells were pre-incubated with drugs at 37° C. for 30 minutes.The migrating reaction was made in RPMI-1640 culture media containing 20mmol/L HEPES, 0.5% BSA. The cells migrated to the lower layer wererecovered, and the number of the cells was counted by Coulter Counter.The inhibitory rate (%) against the migration by the drug of eachconcentration was calculated by the following formula, and IC₅₀ valuewas calculated from such inhibitory rate.${{inhibition}\quad{{rate}(\%)}} = {100 \times \left( {1 - \frac{\begin{matrix}{{{the}\quad{number}\quad{of}\quad{migrated}\quad{cells}}\quad} \\{\quad{{at}\quad{the}\quad{presence}\quad{of}\quad a\quad d}} \\{{rug}\quad{of}\quad{each}\quad{concentration}}\end{matrix} - \begin{matrix}{{the}\quad{number}\quad{of}\quad{migrated}} \\{{{cells}\quad{without}\quad{SDF}} - {1\alpha}}\end{matrix}}{\begin{matrix}{{the}\quad{number}\quad{of}\quad{migrated}} \\{{cells}\quad{without}\quad a\quad{drug}}\end{matrix} - \begin{matrix}{{the}\quad{number}\quad{of}\quad{migrated}} \\{{{cells}\quad{without}\quad{SDF}} - {1\quad\alpha}}\end{matrix}}} \right)}$

As a result, as indicated in FIG. 6, Jurkat cells exhibited strong cellmigration reactivity against SDF-1α. 4F-benzoyl-TN14003 inhibited thisreaction in a dose-dependent manner, and its IC₅₀ value was 0.65 nmol/L.

2. Effects on the Migrating Reaction of Mouse Splenocytes:

Spleens were isolated from BALB/c mice (male, Charles River Japan,Inc.), converted to single cell suspensions, and splenocytes wereprepared by crushing red blood cells.

SDF-1α (Peprotech, final concentration 100 ng/mL) was added to the lowerlayer of Transwell (pore size 5 μm), 1×10⁶/well of the cells (100 μL)were added to the insert, and reacted at 37° C. for 2.5 hours. The cellswere incubated with the drug at 37° C. for 30 minutes. Migratingreaction was made in the RPMI-1640 culture media containing 20 mmol/LHEPES, 0.5% BSA. The number of the cells migrated to the lower layer wascounted by Coulter Counter. Similarly to the preceding clause, theinhibitory rate against the migration by the drug of each concentrationand IC₅₀ value were calculated.

As a result, as indicated in FIG. 7, 4Fbenzoyl-TN14003 inhibited strongmigration reactivity of mouse splenocytes induced by SDF-1 in adose-dependent manner. Its IC₅₀ value was 0.54 mmol/L, and it exhibitedinhibitory activity comparable to the case of human cells. This means inturn that little species difference was identified between humans andmice with respect to this peptide.

EXPERIMENTAL EXAMPLE 9 Effects of 4Fbenzoyl-TN-14003 on MouseDelayed-Type Hypersensitivity Reaction (DTH)

Preserved blood of sheep was purchased from Nippon Bio-Supp. Center. Thepreserved sheep blood was cleansed twice in physiological salinesolution, suspended in physiological saline solution, and used as sheepred blood cells (SRBC). As OD541 nm value of oxyhemoglobin at the timeof hemolyzation of 1.0×10⁹ cells/mL of the SRBC suspension by 14 partsdistilled water is considered to be nearly 0.700, SRBC density wasaccordingly fixed.

2×10⁷ cells/50 μl of SRBC were administered subcutaneously to the anklesof the left hindlimbs of BALB/c mice (male, 6 week-old, Charles RiverJapan, Inc.) and sentisized. After 5 days, 10⁸ cells/50 μl of SRBC wereadministered subcutaneously to the ankles of the right hindlimbs and DTHreaction was induced. Immediately prior to and 24 hours after theinduction of antigens, the thickness of the ankles of the righthindlimbs was measured by a digital micrometer (Mitutoyo CorporationCD-15B), and the increase (mm) in the thickness of ankles was adopted asthe indicator of DTH reaction.

4Fbenzoyl-TN14003 was dissolved to PBS, and continuously administeredusing Alzet osmotic pumps (Alza, 0.5 μL/hr, 7 days persistent type). Theosmotic pumps were implanted intradermally to the backs under etheranesthesia on the day before the sensitization. As the control, pumpsinjected with PBS were similarly implanted. 4F-benzoyl-TN14003 wasadministered at the doses of 4.8, 24 and 120 μg/day.

Data were expressed as mean value±standard margin of error (n=7). ByWilliams test, p 0.025 was valued as significant.

As a result, as indicated in FIG. 8, 4F-benzoyl-TN14003 (4.8, 24 and 120μg/day) inhibited footpad edema dose-dependently and significantly, andthe inhibitory rates were 9, 31 and 51%, respectively. This suggeststhat CXCR4 plays an important role in cellular immunity such as DTHreaction.

EXPERIMENTAL EXAMPLE 10 Therapeutic Effects of 4Fbenzoyl-TN-14003 onMouse Collagen-Induced Arthritis

FK-506 was purified by a known method (Kino T. et al., J. Antibiot.,1987 40(9): 1249-55). Methotrexate was purchased from Wako Pure ChemicalInd., indomethacin from Sigma, bovine type II collagen from CollagenResearch Center (Tokyo, Japan), Freund's complete adjuvant (FCA fromDifco), and anti-mouse IgG2a antibody from Zymed, respectively.

Bovine type II collagen was dissolved to the 2 mg/mL concentration by0.05 mol/L of acetic acid solution, emulsion was prepared with an equalvolume of FCA. 50 μL of the emulsion was injected intradermally at thebase of the tail DBA/1JN mouse (male, 6 week old, Charles River Japan,Inc.) and sensitized. 21 days after the injection, additionalimmunization was made similarly. For 2 weeks after the additionalimmunization, body weights and hindlimb thickness were measured andarthritis scoring was made. Arthritis scores were scored at 0-3 pointsof each limb, and evaluated by the total of the same (12 points beingthe full points; 0, normal; 1, mild swelling or swelling of a singledigit; 2, moderate swelling or swelling of plural digits; 3, severeswelling). Two weeks after the immunization, four limbs and sera werepicked.

After coat blocking bovine type II collagen (10 μg/mL PBS solution) onthe immunoplate, 100 μL of 1000 times diluted mouse serum was added, andkept at room temperature for 2 hours. After cleansing, anti-mouse IgG2aantibody (1000 times dilution) was added. After cleansing, TMB wasadded, kept at room temperature for 30 minutes, H₂SO₄ of equal amountwas added, and A450 nm was measured.

Indomethacin (1 mg/kg), methotrexate (3 mg/kg) and FK-506 (10 mg/kg)were suspended to 0.5% methyl cellulose, and orally administered everyday for 2 weeks from the day of the additional immunization at the doseof 0.1 mL/10 g body weight. 0.5% methyl cellulose solution of the equaldose was orally administered to the control group. 4Fbenzoyl-TN14003 wasdissolved to PBS, and continuously administered using Alzet osmoticpumps (Alza, 0.5 μL/hr 2 weeks). The osmotic pumps were implantedintradermally to the backs of the mice under ether anesthesia on the daybefore the additional immunization. As the control, pumps injected withPBS were similarly implanted. Evaluation of each drug was made for thevalue obtained 2 weeks after the additional immunization.

Data were expressed as mean value±standard margin of error (n=8-12).Comparison between 2 groups was made by Student's t-test, p 0.05 wasvalued as significant. Multiple comparison was made by Dunnett test, p0.05 was valued as significant.

As a result, all of Indomethacin (1 mg/kg, p.o.), methotrexate (3 mg/kg,p.o.) and FK-506 (10 mg/kg, p.o.) significantly inhibited hindlimbswelling, and exhibited significant or evident inhibitory activityagainst arthritis score (FIG. 9).

4F-benzoyl-TN14003 (120 μg/day) exhibited significant inhibitoryactivity against hindlimb swelling, arthritis score and body weightloss. It also showed an inhibitory tendency against increase ofanti-type II collagen specific IgG2a antibody value (FIG. 10). Theseinhibitory effects were equivalent to or better than those of theabove-mentioned known drugs.

INDUSTRIAL APPLICABILITY

The peptidic compounds of the present invention having CXCR4antagonistic activity can inhibit the interaction of CXCR4 andCXCL12/SDF-1α, and accordingly, can inhibit the migrating reaction ofcancerous cells of cancers impressing CXCR4, for example, oral cancer,throat cancer, lip cancer, lingual cancer, gingival cancer,nasopharyngeal cancer, esophageal cancer, gastric cancer, smallintestinal cancer, large intestinal cancer including colorectal cancer,liver cancer, gallbladder cancer, pancreatic cancer, nasal cancer, lungcancer, bone cancer, soft tissue cancer, skin cancer, melanoma, breastcancer, uterine cancer, ovarian cancer, prostate cancer, testicularcancer, penile cancer, bladder cancer, kidney cancer, brain cancer,thyroid cancer, lymphoma, leukemia, etc., and are useful as drugs forthe prevention and/or therapy of these cancers. Also, the peptidiccompounds of the present invention can inhibit the migrating reaction ofimmunocytes induced by CXCL12/SDF-1α and are useful as drugs for theprevention and/or therapy of chronic rheumatoid arthritis.

1. A peptide according to formula (I) or a salt thereof: 1 2 3 4 5 6 7 89 10 11 12 13 14A1-A2-A3-Cys-Tyr-A4-A5-A6-A7-A8-A9-A10-Cys-A11  (I) wherein: A1 is anarginine, lysine, ornithine, citrulline, alanine or glutamic acidresidue which is derivatized at the N-terminal, or A1 is deleted; A2represents an arginine or glutamic acid residue if A1 is an arginine,lysine, ornithine, citrulline, alanine or glutamic acid residue whichmay be derivatized at the N-terminal, or A2 represents an arginine orglutamic acid residue which may be derivatized at the N-terminal if A1is deleted; A3 represents an aromatic amino acid residue; A4, A5 and A9each independently represents an arginine, lysine, ornithine,citrulline, alanine or glutamic acid residue; A6 represents a proline,glycine, ornithine, lysine, alanine, citrulline, arginine or glutamicacid residue; A7 represents a proline, glycine, ornithine, lysine,alanine, citrulline or arginine residue; A8 represents a tyrosine,phenylalanine, alanine, naphthylalanine, citrulline or glutamic acidresidue; A10 represents a citrulline, glutamic acid, arginine or lysineresidue; A11 represents an arginine, glutamic acid, lysine or citrullineresidue which may be derivatized at C-terminal; wherein the cysteineresidues of the 4-position and the 13-position can form a disulfidebond, and the amino acid can be either L or D form.
 2. The peptideaccording to claim 1, wherein A1 is an arginine, citrulline, alanine orglutamic acid residue which is derivatized at the N-terminal, or A1 isdeleted; A2 represents an arginine or glutamic acid residue if A1 is anarginine, citrulline, alanine or glutamic acid residue which may bederivatized at the N-terminal, or A2 represents an arginine or glutamicacid residue which may be derivatized at N-terminal if A1 is deleted; A4represents an arginine, citrulline, alanine or glutamic acid residue; A5represents an arginine, citrulline, alanine, lysine or glutamic acidresidue; A6 represents a lysine, alanine, citrulline or glutamic acidresidue; A7 represents a proline or alanine residue; A8 represents atyrosine, alanine or glutamic acid residue; A9 represents an arginine,citrulline or glutamic acid residue; A10 represents a citrulline orglutamic acid residue; A11 represents an arginine or glutamic acidresidue which may be derivatized at the C-terminal.
 3. The peptideaccording to claim 1, wherein A1 is a glutamic acid residue which isderivatized at the N-terminal, or A1 is deleted.
 4. (canceled)
 5. Thepeptide according to claim 1, wherein any one of A2, A4, A6, A8, and A9is a glutamic acid residue.
 6. (canceled)
 7. The peptide according toclaim 1, wherein A5 represents an arginine or glutamic acid residue. 8.The peptide or its salt claim 7, wherein A5 represents a glutamic acidresidue.
 9. The peptide according to claim 1, wherein A10 represents aglutamic acid, arginine or lysine residue.
 10. The peptide according toclaim 1, wherein A11 represents a glutamic acid, lysine or citrullineresidue. 11.-13. (canceled)
 14. A peptide having the sequence as setforth in any one of SEQ ID NOS: 11-68 or a salt thereof: (1)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO.11); (2)Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO.12); (3)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO.13); (4)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-OH (SEQ IDNO.14); (5)Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO.15); (6)Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO.16); (7)Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-OH (SEQ IDNO.17); (8)Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-OH (SEQ IDNO.18); (9)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.19); (10)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂ (SEQ IDNO.20); (11)Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.21); (12)Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.22); (13)Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂ (SEQ IDNO.23); (14)Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂ (SEQ IDNO.24); (15)H-DGlu-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO.25); (16)H-Arg-Glu-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO.26); (17)H-Arg-Arg-Nal-Cys-Tyr-Glu-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO.27); (18)H-Arg-Arg-Nal-Cys-Tyr-Arg-Glu-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO.28); (19)H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO.29); (20)H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Glu-Cit-Cys-Arg-OH (SEQ IDNO.30); (21)H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Glu-OH (SEQ IDNO.31); (22)H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.32); (23)H-Arg-Arg-Nal-Cys-Tyr-DGlu-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.33); (24)H-Arg-Arg-Nal-Cys-Tyr-DGlu-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.34); (25)H-DGlu-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.35); (26)H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-DGlu-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.36); (27)H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-DGlu-Cys-Arg-NH₂ (SEQ IDNO.37); (28)Ac-DGlu-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.38); (29)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-DGlu-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.39); (30)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-DGlu-Cys-Arg-NH₂ (SEQ IDNO.40); (31)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.41); (32)guanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQID NO.42); (33)TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO.43); (34)TMguanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQID NO.44); (35)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO.45); (36)2F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO.46); (37)APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.47); (38)desamino-R-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQID NO.48); (39)guanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.49); (40)succinyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQID NO.50); (41)glutaryl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQID NO.51); (42)deaminoTMG-APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO.52); (43)nelfinaviryl-succinyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO.53); (44)AZT-glutaryl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO.54); (45)R—CH2-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.55); (46) H-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO.56); (47)TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO.57); (48)ACA-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.58); (49)ACA-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO.59); (50)H-Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.60); (51)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.61); (52)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.62); (53)Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO.63); (54)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO.64); (55)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHMe(SEQ ID NO.65); (56)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHEt(SEQ ID NO.66); (57)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHiPr(SEQ ID NO.67); (58)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-tyramine(SEQ ID NO.68); wherein, in each sequence, the symbol appearing as partof N-terminal amino acid shows derivatization or non-derivatization ofthe amino group; H shows non-derivatization, Ac shows acetyl group,guanyl shows guanyl group, succinyl shows succinyl group, glutaryl showsglutaryl group, TMguanyl shows tetra-methyl guanyl group, 2F-benzoylshows 2-fluorobenzoyl group, 4F-benzoyl shows 4-fluorobenzoyl group, APAshows 5-amino-pentanoyl group, ACA shows 6-amino-hexanoyl group,desamino-R shows 2-desamino-arginyl group, deaminoTMG-APA shows thefollowing formula (II),

nelfinaviryl-succinyl shows the following formula (III),

AZT-glutaryl shows the following formula (IV),

R—CH² shows the following formula (V)

Arg shows L-arginine residue, Nal show L-3-(2-naphtyl)alanine residue,Cys shows L-cysteine residue, Tyr shows L-tyrosine residue, Cit showsL-citrulline residue, Lys shows L-lysine residue, DLys shows D-lysineresidue, Pro shows L-proline residue, DCit shows D-citrulline residue,DGlu shows D-glutamic acid residue, Glu shows L-glutamic acid residue, 2cysteine residues are combined by intramolecular disulfide bond, thesymbol attached to the right part of C-terminal amino acid showsderivatization or non-derivatization of carboxyl group, OH showsnon-derivatization, NH₂ shows amidation by amino group, NHMe showsamidation by methyamino group, NHEt shows amidation by ethylamino group,NHiPr shows amidation by isopropylamino group, tyramine shows amidationby p-hydroxyphenylethylamino group.
 15. A pharmaceutical compositioncomprising a peptide according to formula (I) or a salt thereof. 16.(canceled)
 17. A method for preventing or treating cancers or chronicrheumatoid arthritis in a subject in need thereof, comprisingadministering to the subject a pharmaceutical composition comprising asan active ingredient a therapeutically effective amount of a peptideaccording to formula (I) or a salt thereof: 1 2 3 4 5 6 7 8 9 10 11 1213 14A1-A2-A3-Cys-Tyr-A4-A5-A6-A7-A8-A9-A10-Cys-A11  (I) wherein: A1 is anarginine, lysine, ornithine, citrulline, alanine or glutamic acidresidue which is derivatized at the N-terminal, or A1 is deleted; A2represents an arginine or glutamic acid residue if A1 is an arginine,lysine, ornithine, citrulline, alanine or glutamic acid residue whichmay be derivatized at the N-terminal, or A2 represents an arginine orglutamic acid residue which may be derivatized at the N-terminal if A1is deleted; A3 represents an aromatic amino acid residue; A4, A5 and A9each independently represents an arginine, lysine, ornithine,citrulline, alanine or glutamic acid residue; A6 represents a proline,glycine, ornithine, lysine, alanine, citrulline, arginine or glutamicacid residue; A7 represents a proline, glycine, ornithine, lysine,alanine, citrulline or arginine residue; A8 represents a tyrosine,phenylalanine, alanine, naphthylalanine, citrulline or glutamic acidresidue; A10 represents a citrulline, glutamic acid, arginine or lysineresidue; A11 represents an arginine, glutamic acid, lysine or citrullineresidue which may be derivatized at the C-terminal; wherein the cysteineresidues of the 4-position and the 13-position can form a disulfidebond, and the amino acid can be either L or D form.
 18. The methodaccording to claim 17 wherein cancer is breast cancer or pancreaticcancer. 19.-22. (canceled)
 23. The peptide according to claim 14 havingthe sequence as set forth in SEQ ID NO: 45 or in SEQ ID NO:
 64. 24. Thepharmaceutical composition according to claim 15, wherein: A1 is anarginine, citrulline, alanine or glutamic acid residue which isderivatized at the N-terminal, or A1 is deleted; A2 represents anarginine or glutamic acid residue if A1 is an arginine, citrulline,alanine or glutamic acid residue which may be derivatized at N-terminal,or A2 represents an arginine or glutamic acid residue which may bederivatized at the N-terminal if A1 is deleted; A4 represents anarginine, citrulline, alanine or glutamic acid residue; A5 represents anarginine, citrulline, alanine, lysine or glutamic acid residue; A6represents a lysine, alanine, citrulline or glutamic acid residue; A7represents a proline or alanine residue; A8 represents a tyrosine,alanine or glutamic acid residue; A9 represents an arginine, citrullineor glutamic acid residue; A10 represents a citrulline or glutamic acidresidue; A11 represents an arginine or glutamic acid residue which maybe derivatized at the C-terminal.
 25. The pharmaceutical compositionaccording to claim 15, wherein A1 is a glutamic acid residue which isderivatized at the N-terminal, or A1 is deleted.
 26. The pharmaceuticalcomposition according to claim 15, wherein any one of A2, A4, A6, A8 andA9 is a glutamic acid residue.
 27. The pharmaceutical compositionaccording to claim 15, wherein A5 represents an arginine or glutamicacid residue.
 28. The pharmaceutical composition according to claim 15,wherein A5 represents a glutamic acid residue.
 29. The pharmaceuticalcomposition according to claim 15, wherein A10 represents a glutamicacid, arginine or lysine residue.
 30. A pharmaceutical compositionaccording to claim 15, wherein A11 represents a glutamic acid, lysine orcitrulline residue.
 31. A pharmaceutical composition comprising apeptide having the sequence as set forth in any one of SEQ ID NOS: 11-68or a salt thereof: (1)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 11); (2)Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 12); (3)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 13); (4)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-OH (SEQ IDNO. 14); (5)Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 15); (6)Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 16); (7)Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-OH (SEQ IDNO. 17); (8)Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-OH (SEQ IDNO. 18); (9)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 19); (10)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂ (SEQ IDNO. 20); (11)Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 21); (12)Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 22); (13)Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂ (SEQ IDNO. 23); (14)Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂ (SEQ IDNO. 24); (15)H-DGlu-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 25); (16)H-Arg-Glu-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 26); (17)H-Arg-Arg-Nal-Cys-Tyr-Glu-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 27); (18)H-Arg-Arg-Nal-Cys-Tyr-Arg-Glu-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 28); (19)H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 29); (20)H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Glu-Cit-Cys-Arg-OH (SEQ IDNO. 30); (21)H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Glu-OH (SEQ IDNO. 31); (22)H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 32); (23)H-Arg-Arg-Nal-Cys-Tyr-DGlu-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 33); (24)H-Arg-Arg-Nal-Cys-Tyr-DGlu-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 34); (25)H-DGlu-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 35); (26)H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-DGlu-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 36); (27)H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-DGlu-Cys-Arg-NH₂ (SEQ IDNO. 37); (28)Ac-DGlu-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 38); (29)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-DGlu-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 39); (30)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-DGlu-Cys-Arg-NH₂ (SEQ IDNO. 40); (31)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 41); (32)guanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQID NO. 42); (33)TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO. 43); (34)TMguanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQID NO. 44); (35)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO. 45); (36)2F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO. 46); (37)APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ ID NO.47); (38)desamino-R-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQID NO. 48); (39)guanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 49); (40)succinyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQID NO. 50); (41)glutaryl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQID NO. 51); (42)deaminoTMG-APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO. 52); (43)nelfinaviryl-succinyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO. 53); (44)AZT-glutaryl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO. 54); (45)R—CH2-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 55); (46) H-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO. 56); (47)TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO. 57); (48)ACA-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 58); (49)ACA-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 59); (50)H-Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 60); (51)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 61); (52)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 62); (53)Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 63); (54)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO. 64); (55)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHMe(SEQ ID NO. 65); (56)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHEt(SEQ ID NO. 66); (57)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NhiPr(SEQ ID NO. 67); (58)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-tyramine(SEQ ID NO. 68).
 32. The pharmaceutical composition according to claim31, comprising a peptide having the sequence as set forth in SEQ ID NO:45 or in SEQ ID NO:
 64. 33. The method according to claim 17, whereinsaid peptide is a CXCR4 antagonist.
 34. The method according to claim17, wherein: A1 is an arginine, citrulline, alanine or glutamic acidresidue which is derivatized at the N-terminal, or A1 is deleted; A2represents an arginine or glutamic acid residue if A1 is an arginine,citrulline, alanine or glutamic acid residue which may be derivatized atthe N-terminal, or A2 represents an arginine or glutamic acid residuewhich may be derivatized at the N-terminal if A1 is deleted; A4represents an arginine, citrulline, alanine or glutamic acid residue; A5represents an arginine, citrulline, alanine, lysine or glutamic acidresidue; A6 represents a lysine, alanine, citrulline or glutamic acidresidue; A7 represents a proline or alanine residue; A8 represents atyrosine, alanine or glutamic acid residue; A9 represents an arginine,citrulline or glutamic acid residue; A10 represents a citrulline orglutamic acid residue; A11 represents an arginine or glutamic acidresidue which may be derivatized at the C-terminal.
 35. The methodaccording to claim 17, wherein A1 is a glutamic acid residue which isderivatized at the N-terminal, or A1 is deleted.
 36. The methodaccording to claim 17, wherein any one of A2, A4, A6, A8 and A9 is aglutamic acid residue.
 37. The method according to claim 17, wherein A5represents an arginine or glutamic acid residue.
 38. The methodaccording to claim 17, wherein A5 represents a glutamic acid residue.39. A method for preventing or treating cancers or chronic rheumatoidarthritis in a subject in need thereof, comprising administering to thesubject a pharmaceutical composition comprising as an active ingredienta therapeutically effective amount of a peptide having the sequence asset forth in any one of SEQ ID NOS: 11-68 or a salt thereof: (1)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 11); (2)Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 12); (3)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 13); (4)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-OH (SEQ IDNO. 14); (5)Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 15); (6)Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 16); (7)Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-OH (SEQ IDNO. 17); (8)Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-OH (SEQ IDNO. 18); (9)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 19); (10)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂ (SEQ IDNO. 20); (11)Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 21); (12)Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 22); (13)Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂ (SEQ IDNO. 23); (14)Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂ (SEQ IDNO. 24); (15)H-DGlu-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 25); (16)H-Arg-Glu-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 26); (17)H-Arg-Arg-Nal-Cys-Tyr-Glu-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 27); (18)H-Arg-Arg-Nal-Cys-Tyr-Arg-Glu-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 28); (19)H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 29); (20)H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Glu-Cit-Cys-Arg-OH (SEQ IDNO. 30); (21)H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Glu-OH (SEQ IDNO. 31); (22)H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 32); (23)H-Arg-Arg-Nal-Cys-Tyr-DGlu-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 33); (24)H-Arg-Arg-Nal-Cys-Tyr-DGlu-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 34); (25)H-DGlu-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 35); (26)H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-DGlu-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 36); (27)H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-DGlu-Cys-Arg-NH₂ (SEQ IDNO. 37); (28)Ac-DGlu-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 38); (29)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-DGlu-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 39); (30)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-DGlu-Cys-Arg-NH₂ (SEQ IDNO. 40); (31)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 41); (32)guanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQID NO. 42); (33)TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO. 43); (34)TMguanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQID NO. 44); (35)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO. 45); (36)2F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO. 46); (37)APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ ID NO.47); (38)desamino-R-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQID NO. 48); (39)guanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 49); (40)succinyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQID NO. 50); (41)glutaryl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQID NO. 51); (42)deaminoTMG-APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO. 52); (43)nelfinaviryl-succinyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO. 53); (44)AZT-glutaryl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO. 54); (45)R—CH2-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 55); (46) H-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO. 56); (47)TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO. 57); (48)ACA-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 58); (49)ACA-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH (SEQ IDNO. 59); (50)H-Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 60); (51)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 61); (52)Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 62); (53)Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (SEQ IDNO. 63); (54)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂(SEQ ID NO. 64); (55)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHMe(SEQ ID NO. 65); (56)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHEt(SEQ ID NO. 66); (57)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NhiPr(SEQ ID NO. 67); (58)4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-tyramine(SEQ ID NO. 68).
 40. The method according to claim 39 wherein saidpeptide having the sequence as set forth in SEQ ID NO: 45 or in SEQ IDNO: 64.